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Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Patients experience
the effects of AF from early symptom onset to treatment and beyond. A previous qualitative
study found AF to substantially affect patients’ emotional wellbeing, social relationships,
employment, and finances. Existing quality of life questionnaires do not adequately assess
the AF impact. In this thesis, a new patient-reported questionnaire was developed to measure
the impact of AF as experienced by patients. An exploratory factor analysis was conducted
on the new questionnaire, revealing five domains: “Affect”, “Social Support”, “Major Life
Events”, “Financial Impact”, and “Diagnostic Experience”. Age, marital status, educational
attainment, and time of last episode were significantly associated with the overall score.
Female gender was associated with a worse diagnostic experience after adjusting for
covariates, confirming previous qualitative findings. The new questionnaire has good internal
consistency and can be used to study variables associated with the AF impact.
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Summary for Lay Audience
The normal heart rate for adults at rest ranges from 60 to 100 beats per minute. Apart from
rate, the normal heart also follows a characteristic rhythm that can be detected on an
electrocardiogram. Departures from a regular rate or rhythm are referred to as arrhythmias.
Atrial fibrillation (AF) is the most common sustained arrhythmia where the heart beats too
fast or too slow and out of rhythm. Patients with AF can often feel their hearts pounding or
racing and experience symptoms such as chest pain, shortness of breath, difficulty exercising,
dizziness, and fatigue. AF can affect a patient’s wellbeing as soon as they begin to
experience symptoms. Previously, focus groups and interviews with patients revealed that
getting a diagnosis of AF was difficult because some physicians did not take patients’
symptoms seriously. It was also found that AF affected patients’ emotional wellbeing, social
relationships, employment, and personal finances.
We developed a questionnaire, called Mapping the Impact of Atrial Fibrillation (MAP-AF),
and used it to study the life impacts of AF on patients. A statistical technique called factor
analysis allowed us to determine the different areas of peoples’ lives that AF impacts. By
examining these areas, or “domains”, we were able to see whether the MAP-AF measures
what it was supposed to measure. We found five domains underlying 16 questions. They
were “Affect”, or mood, “Social Support”, “Major Life Events”, “Financial Impact”, and
“Diagnostic Experience”. The MAP-AF allows us to calculate a total score and a score for
each of the five domains for each person. We found patients who were younger, divorced or
separated, completed high school or below, or experienced a recent AF episode had higher
total scores and were more impacted by AF. Confirming previous findings, our results
showed female patients to score higher (i.e., worse) on “Diagnostic Experience” than male
patients. After our results are confirmed in a separate group of patients, the MAP-AF
questionnaire can be used to study how AF affects the wellbeing of patients, identify patient
needs, and improve healthcare services. Timely diagnosis and empathetic care are essential
for patient-centered AF management.
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Chapter 1

1

Introduction

Departures from the normal heart rate or rhythm are referred to as arrhythmias1. Atrial
fibrillation (AF) is the most common sustained arrhythmia and is associated with
symptoms such as palpitations, chest pain, dyspnea, exercise intolerance, dizziness, and
fatigue2,3. The sometimes transient nature of AF episodes and symptoms can present
challenges to diagnosis.
AF can affect a patient’s wellbeing in many ways. For instance, the uncertainty
associated with the onset of symptoms can create anxiety for many patients, which can be
worse if physicians do not take patients’ concerns and symptoms seriously. After patients
are treated, their symptoms may be alleviated, but they can also experience side effects
and restrictions to their lifestyle. For example, patients taking blood thinners to prevent
strokes may avoid physical activities out of the fear of bleeding4,5. Research is needed to
understand how patients experience the effects of AF.
This thesis is the quantitative phase of the two-phase mixed methods exploratory
sequential design, aimed at addressing the impact of AF on patients. Our research follows
the “instrument development model” of the exploratory design described by Creswell and
Plano Clark (2007)6. In this model, qualitative data (e.g., quotes from interviews) are
collected first to explore a phenomenon. The qualitative information is then used to
inform the development of a measure (e.g., a questionnaire), which will be used to collect
data for quantitative analysis. The qualitative and quantitative phases are connected
through the development of questionnaire items6. This type of research design is
particularly helpful for understanding and measuring subjective and latent constructs like
wellbeing and quality of life.
The qualitative phase involved two studies. The first was a Canada-wide project funded
by the Cardiac Arrhythmia Network of Canada (CANet). Led by Dr. Mary Runte, the
project utilized focus groups, narrative interviews, and patient journey mapping to solicit
the patient view of the arrhythmia impact. Patients in this study came from eight different
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Canadian cities and had various arrhythmic conditions, not limited to AF. The project
specifically looked at the economic, employment, social, emotional, and psychological
impact of arrhythmias from symptom-onset to treatment and beyond7. To our knowledge,
this is the first large scale project on the arrhythmia patient journey in Canada. The
second study was a secondary analysis of the first study (Chang J et al., unpublished data,
May 2021). It analyzed only quotes and patient journey maps of AF patients and used the
results to inform concerns that are important to AF patients. The study then identified
existing patient-reported measures and compared the content of these measures to themes
emerged from the quotes of AF patients. Existing quality of life questionnaires were
deemed inadequate for assessing the full impact of AF. The results of this (i.e., second)
qualitative study will be used to develop items for a new questionnaire that will capture
the AF impact in a holistic manner.
This thesis will describe the development and initial validation of a new questionnaire,
Mapping the Impact of Atrial Fibrillation (MAP-AF), in a sample of AF patients in
London, Ontario. The initially validated MAP-AF questionnaire will then be used for
scoring, and we will explore the relationship between the MAP-AF scores and selected
covariates (including demographic and clinical variables).

1.1 Objectives
The objectives of this thesis are presented below.
I. To generate items for a new questionnaire (MAP-AF) based on previous
qualitative research
II. To determine the factor structure of the MAP-AF questionnaire using
exploratory factor analysis and to evaluate each factor’s internal consistency using
Cronbach’s alpha
III. To compute factor scores and an overall score that will be used for hypothesis
testing and in regression models to identify important predictors
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1.2 Thesis organization
This thesis is written in a monograph format. Chapter 2 is a literature review on atrial
fibrillation and patient-reported measures. It includes a description of the qualitative
study we previously conducted (Chang J et al., unpublished data, May 2021) that
compared existing quality of life questionnaires to findings from focus groups and
interviews with AF patients. The qualitative study highlights the limitations of existing
questionnaires and serves as the basis for our questionnaire development.
Briefly, Chapter 3 will describe the development and validation of the MAP-AF
questionnaire, and Chapter 4 will describe the analyses of the questionnaire scores. Since
the methods of Chapter 4 depend entirely on the results of Chapter 3, both Chapters have
their own methods and results sections.
In Chapter 3, we describe the methods and results of generating items for the new
questionnaire, factor analyzing the questionnaire, and removing items with suboptimal
measurement properties.
In Chapter 4, we describe the methods and results of score computation, hypothesis
testing, statistical regression for model selection, and multivariable linear regression of
the overall (total) score on selected predictors.
Chapter 5 will discuss the results from both Chapters 3 and 4. We will also describe the
implications, strengths, and limitations of this thesis and make suggestions for future
research.
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Chapter 2

2

Literature review and qualitative research

2.1 Atrial fibrillation: overview
Irregular rate or rhythm of the heart is referred to as an arrhythmia1. Atrial fibrillation
(AF), the most common sustained cardiac arrhythmia, is associated with significant
morbidity, mortality, and healthcare burden2. As estimated by the Global Burden of
Disease project, 46.3 million individuals around the world were living with AF or atrial
flutter in 20163. Prevalence of AF is higher in developed countries, especially in Northern
Europe and the United States (US), and lower in the Asia-Pacific area3,4.
The incidence and prevalence of AF are expected to rise globally as a result of population
aging, increasing prevalence of AF risk factors, and enhanced AF detection2,4-6. By 2030,
14 – 17 million individuals in the European Union are expected to have AF2; by 2050, 6 –
16 million individuals in the US alone are anticipated to have AF6.
While the arrhythmia itself is not fatal, AF-related complications like heart failure (HF),
tachycardia induced cardiomyopathy, and stroke put AF patients at an elevated risk of
cardiovascular and all-cause mortality2,6,7. AF is associated with a 2- to 5-fold increase in
the risk of stroke 4,6,8, and 20% – 30% of all ischemic strokes are attributable to AF2.
Additional morbidity includes cognitive impairment (e.g., vascular dementia) and
cardiovascular morbidity (e.g., cardiomyopathy, left ventricular dysfunction) 2,9.
From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
(ORBIT-AF) study, 31% of AF patients had one or more hospitalizations after a one-year
follow-up10. Another population-based study in the US found that 1.5% of all
hospitalizations listed AF as the primary cause, and 12% of all hospitalizations listed AF
as a secondary cause or comorbidity7. The cost of emergency department visits and
hospitalizations related to AF represents a significant burden on the healthcare system2.
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2.1.1

Diagnosis and classification

AF rhythm is characterized by irregular RR intervals and the absence of distinct P waves
on the electrocardiogram2,9. In contrast, atrial flutter typically has atrial activity with a
“saw tooth” morphology2. According to the European Society of Cardiology (ESC)
guidelines, clinical AF is diagnosed when an electrocardiography (ECG) documented AF
episode lasts at least 30 seconds. The standard diagnostic procedure for patients reporting
AF symptoms or patients who had a recent cryptogenic stroke involves a 12-lead ECG in
the clinic. If the 12-lead ECG does not indicate ongoing AF, a 24/48-hour Holter monitor
or other prolonged ECG monitoring methods (e.g., 7- to 30-day event monitors) are
attempted to document AF11.
AF can be clinically classified into paroxysmal or persistent based on the duration and
frequency of arrhythmic episodes12. According to the latest Canadian Cardiovascular
Society (CCS) guidelines for AF management, paroxysmal AF is defined as “a
continuous AF episode lasting longer than 30 seconds but terminating within 7 days of
onset” and persistent AF as “a continuous AF episode lasting longer than 7 days but less
than 1 year”12. Paroxysmal AF that is short-lasting and intermittent may not be present
during 12-lead ECG or 24/48-hour Holter monitoring – in this case, repeated and
prolonged monitoring may be necessary to diagnose AF11. Progression from paroxysmal
to more persistent forms of AF is common when AF is left untreated2.
Besides overt clinical AF, there is also silent atrial fibrillation (SAF), where patients are
asymptomatic and unaware of their arrhythmia4. It is estimated that approximately onethird of all AF is asymptomatic and subclinical4,5,13. Despite the absence of symptoms,
the prognostic impact of SAF is considered to be the same as symptomatic clinical AF4,14.
Therefore, delays in diagnosis can allow the disease to progress to more severe forms and
exacerbate the risk of stroke and other complications12. Unfortunately, SAF often remains
undetected until a patient experiences an adverse effect of AF and presents to the
emergency department with a cryptogenic stroke or congestive heart failure4,5,15. SAF
may also be incidentally detected by implanted pacemakers or during routine
physicals4,5,15.
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Recently, promising screening devices that are non-invasive (i.e., smartwatches) have
been developed to enhance AF detection and expedite treatment initiation12.

2.1.2

Symptoms

Symptoms related to AF are highly variable between individuals and in the same
individuals over time13. The most common symptoms, however, are palpitations, chest
pain, and exercise intolerance13. Other symptoms reported by patients include dyspnea,
sleeping difficulties, dizziness, psychosocial distress, and fatigue2,13. In some patients,
syncope and presyncope can be present13. Not all symptoms reported are attributable to
AF because risk factors and comorbidities of AF may also produce similar symptoms13.
Symptom severity and burden can be assessed and classified by a number of instruments.
The CCS 2020 guidelines described four symptom severity scales12:
The European Heart Rhythm Association (EHRA) Classification and the Canadian
Cardiovascular Society Severity of Atrial Fibrillation Scale (CCS – SAF) are two
clinician-reported measures; the University of Toronto Atrial Fibrillation Severity Scale
(AFSS) and the Atrial Fibrillation Symptom Severity and Burden (AFS/B) scale are two
patient-reported measures12.
As mentioned earlier, asymptomatic AF is considered to have the same prognostic
impact as symptomatic AF4,14. Even if successful treatment alleviates symptoms for
symptomatic patients, it may not eliminate AF or its associated stroke risk. Stroke
prevention is continued in patients even after symptoms appear to be remedied. In
addition, symptom alleviating treatment may not necessarily improve patients’ perceived
wellbeing because of side effects, hospitalizations, and other factors. Two studies found
that symptom severity does not correlate well with global life satisfaction, and quality of
life may be reduced even in asymptomatic individuals5,16.
Gender and sex-based analyses in health can provide valuable insight into biological
differences and potential health disparities. Using the EHRA symptom classification
scale, one study found that female patients with AF reported more frequent and severe
symptoms compared to male patients17. Regardless of gender, participants in the study
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most commonly experienced fatigue, dyspnea, and palpitations17. Similarly, Westerman
and Wenger (2019)18 reviewed four studies that all found women to be more
symptomatic17,19-21.

2.1.3

Management

Current management of AF consists of anticoagulation for stroke prevention, risk factor
and comorbidity management, and rate and/or rhythm control8,9,22-24. Timely initiation of
management is critical to reduce symptoms and complications and slow the progression
of AF4.
Following diagnosis, stroke and bleeding risk are assessed to guide decisions to
anticoagulate. While the CHADS2 is the reference tool for stratifying stroke risk in
clinical guidelines, the CHA2DS2-VASc score is more commonly used in clinical
practice8,25,26. The letters “CHADS” stands for congestive heart failure, hypertension,
age ≥ 75, diabetes, and stroke; and “VASc” stands for vascular disease, age 65-74, and
sex category female9,25,26. The numeric “2” distinguishes factors with a much higher risk
of stroke, for which 2 points (one additional point on the score) are warranted. A higher
score on both instruments indicates a greater need for anticoagulation.
Warfarin and oral anticoagulants (OAC) effectively reduce the risk of stroke but can
produce side effects such as major bleeding8,9. An individual with a high risk of bleeding,
as assessed by scales like the HAS-BLED score, may be a candidate for percutaneous left
atrial appendage occlusion instead of OAC for stroke prevention9,27.
While stroke prevention reduces stroke-related mortality, cardiovascular mortality due to
other causes is still common in anticoagulated individuals2. Risk factors, underlying
disease, and comorbidity management are essential to reduce other causes of mortality.
Alongside stroke prevention, ventricular rate control should be initiated for recent-onset
AF patients. The most common pharmacologic rate control interventions are β-blockers
and non-dihydropyridine calcium channel antagonists, both of which can slow the atrial
fibrillation heart rate to a target range2,8.
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Acute rhythm control may be pursued as first-line therapy for severely compromised
patients. Otherwise, it is indicated when ventricular rate control fails to adequately
alleviate symptoms. For patients with persistent AF, sinus rhythm can be restored by
pharmacologic cardioversion (antiarrhythmic drugs) or direct current cardioversion along
with a rhythm medication to maintain sinus rhythm once it is restored.
Amiodarone is both a rate and rhythm control drug8,9. While it is more efficacious than
other antiarrhythmic drugs, it should be reserved for highly symptomatic patients because
of its potential for long-term adverse side effects8,9.
For patients who remain symptomatic despite rate and rhythm control medications,
catheter ablation targeting the pulmonary veins can be considered9. Pulmonary vein
ablation has been found to effectively restore sinus rhythm, improve quality of life, and
reduce hospital admissions8.
Atrio-ventricular nodal ablation with pacing is another type of ablation procedure. In
contrast to pulmonary vein ablation, which is a form of rhythm control, atrio-ventricular
nodal ablation can deliver permanent rate control without the need for rate
medications9,28. It is an option for whom pharmacological rate control fails and rhythm
control strategies are deemed inappropriate (due to their inherent risks and timeline).
AF management is complicated by concomitant conditions. The 2018 Focused Update of
the Canadian Cardiovascular Society Guidelines for the Management of Atrial
Fibrillation highlighted seven advancements in AF management, including catheter
ablation for AF patients with HF and antithrombotic therapy for patients with coronary
artery disease23.
Interestingly, two review articles found sex differences in AF management18,29. For
example, women were less likely to receive electrical cardioversion or ablation than
men17,18,29.
Overall, patients with AF face unique challenges. Patients experiencing intermittent
episodes of AF may need to frequent medical centers and require prolonged monitoring
for a diagnosis. Furthermore, AF symptoms are highly variable. Even in the absence of
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symptoms, AF is associated with increased stroke risk and complications that will require
ongoing management. Patients navigating through the AF illness experience are faced
with much uncertainty. We will be able to better address patient needs and preferences
with a patient-centered care approach to AF management.

2.2 Patient-centered care
Patient-centered care was a new concept in medicine in the early 50s and had roots in
Carl Rogers’ client-centered therapy. Client-centered therapy emerged from humanistic
psychology in 1951 and revolutionized the therapist-and-client relationship. Clients are to
be treated as active participants in consultations, the therapist as an agent rather than an
authority30. This approach encouraged clients to tell their own stories, believing that
clients know themselves best. Medical psychoanalyst Michael Balint proposed a similar
concept in the medical field, coining the term “patient-centered medicine”31-34.
This new perspective and approach to medicine were, to a large degree, a response to the
limitations of traditional medicine31,35. The traditional biomedical model was “illnesscentered”, interested primarily in localizing disease entities and resolving physiological
aberrations31,35. During this time, physicians practicing under this illness-centered lens
had difficulty helping patients who had complaints but for whom clinical investigations
identified no obvious physical cause36. In response, Balint explained how the doctor’s
affective response might play a role in alleviating or exacerbating the patient’s
illness31,34,36. He further urged physicians to examine patients as whole persons when
making a diagnosis or prescribing treatment 31,34.
Since Balint’s pioneering work, there has been a growing interest and emphasis on
patient-centered care. It is now widely acknowledged as a core value in medicine. In fact,
patient-centered care is one of six establishing aims put forth by the Institute of Medicine
in the US for the 21st-century healthcare system37.
With the growing body of literature on the topic, various definitions of patient-centered
care have been proposed35,38,39. The general consensus is that “patient-centeredness”
means moving away from physician-dominated “dialogue” to actively involving
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participants in their own care (i.e., patient empowerment) and incorporating patient
values and preferences into clinical decision making34,37,38. Akin to Roger’s clientcentered therapy, at the core of patient-centered care is the moral imperative of respecting
patients as unique living beings34,38.
We describe two popularly cited frameworks that aim to clarify the concept of patientcentered care.
In 1995, Stewart and colleagues from the Department of Family Medicine at Western
University (Ontario, Canada) developed a model to define the patient-doctor relationship
and guide clinical practice. Stewart’s “patient-centered clinical method” was inspired by
Dr. Ian R McWhinney and Dr. Joseph Levenstein and initially had six components:
exploring the disease and illness experience, understanding the whole person, finding
common ground, incorporating prevention and health promotion, enhancing the patientclinician relationship, and being realistic34. In 2014, the framework was revised to have
four components, dropping “incorporating prevention and health promotion” and “being
realistic”. The earliest version of the model remains one of the most cited in family
medicine33.
Mead and Bower (2000) reviewed the literature on existing patient-centered care models
(including Stewart’s work) and synthesized aspects of the patient-doctor relationship
characterized by patient-centeredness35. Five key dimensions of patient-centeredness
were proposed by Mead and Bower, including the biopsychosocial perspective, patientas-person, sharing power and responsibility, therapeutic alliance, and doctor-as-person.
Several similarities can be found between the two conceptual frameworks described. We
highlight one similarity in particular – understanding the illness experience – in the
following section.

2.3 Understanding the disease and illness experience – an
essential component of patient-centered care
Understanding the illness experience from the patient’s perspective is essential for
achieving patient-centered care. In both the patient-centered clinical method developed
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by Stewart and colleagues and the five dimensions of the patient-centered doctor-patient
relationship proposed by Mead and Bower, physicians are asked to enter the patient’s
world.
One component of the patient-centered clinical method developed by Stewart and
colleagues (2014) is exploring the patient’s disease and illness experience34. It requires
physicians to appreciate the patient’s feelings about being ill, their ideas about the illness,
their expectations from healthcare providers, and how the illness is affecting their
functioning.
Similarly, both the “biopsychosocial perspective” and “patient-as-person” dimensions of
patient-centeredness proposed by Mead and Bower (2000) call for viewing patients as
“experiencing individuals” rather than “objects of disease entities”35. Mead and Bower
provided a powerful example to illustrate how one disease may affect two individuals in a
completely different manner. While an office worker may be able to resume work
following a leg fracture, a professional athlete may be facing an end of their career with
the same injury. The distress experienced is different for the two individuals. In addition,
treatments do not always alleviate suffering for patients. The side effects and threats to a
patient’s sense of self may be reasons why some patients decline life-saving cancer
treatments. It is imperative to examine the patient’s circumstances and attitudes when
caring for them, as they may help physicians identify the best courses of action35.
Undoubtedly, patients are the ones with the most experience with the disease40.
Understanding the patient’s lived experiences with illness not only helps clinicians
identify patient needs and shortcomings of the healthcare system but is also a means of
achieving patient-centered care.

2.4 Collecting data on the patient perspective
Attributes of patient-centered care are best evaluated using measures of the patient’s
perception33. To learn about the illness experience, we must refer to the experts on this
topic – the patients themselves. Interviews and self-administered questionnaires are
methods to collect information and expertise from patients.
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These questionnaires are generally referred to as “patient-reported measures” and can
measure a variety of concepts. There are two main groups of these measures in the
literature: patient-reported outcome measures and patient-reported experience measures.
The former is primarily used to evaluate the effectiveness of care, and the latter to
evaluate and improve healthcare services.

2.4.1

Effects of care and PROMs

Patient-reported outcome measures (PROMs) assess the patients’ perceived effects of
their care. The “effects” or “outcomes” measured can range from pain level, physical
functioning, symptom severity, to quality of life (QoL)41. Since we are interested in
understanding how disease affects patients’ wellbeing, we will restrict our subsequent
discussion of PROMs to QoL instruments.
One context of the use of PROMs is in clinical trials. For example, a QoL questionnaire
is administered to patients before and after an intervention to assess QoL changes due to
treatment. The US Food and Drug Administration now recognizes QoL improvements,
measured by validated instruments, as an indication or labelling claim on medical
products42,43. It is currently the goal of many questionnaire developers to get their QoL
instruments approved for use in clinical trials. For this purpose, questionnaires need to be
responsive to interventions – that is, items in such questionnaires often measure aspects
of QoL most responsive to health changes.
Quality of life is a theoretical construct that cannot be directly observed or measured44. It
can be understood as “a multidimensional concept that … often involves the concept of
happiness, subjective wellbeing, and the meaning given to life”44. Various interpretations
of QoL exist, and no single definition is used consistently.
The World Health Organization Quality of Life (WHOQOL) Group in 1995 defined QoL
as:
“individuals’ perception of their position in life in the context of the culture and
value systems in which they live and in relation to their goals, expectations,
standards and concerns. It is a broad ranging concept affected in a complex way
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by the person’s physical health, psychological state, level of independence, social
relationships and their relationship to salient features of their environment”45.
This definition recognizes the multidimensionality of QoL and the influence of cultural
and person values on one’s perceived meaning of QoL46,47. Preliminary testing of the
group’s global generic QoL questionnaire, WHOQOL, revealed four domains of QoL:
physical, psychological, social relationships, and environment45. Themes considered
under “environment” include transport[ation], work satisfaction, home environment, and
financial resources45.
Another relevant concept is health-related quality of life (HRQoL), which is also what
many PROMs are said to measure. Unfortunately, various interpretations of HRQoL
exist, leading to substantial confusion around the term44,48. One definition of HRQoL is
aspects of self-perceived wellbeing that are affected by the presence of disease49. In other
words, a measure of how patients are impacted by ill-health50,51. However, this
interpretation of HRQoL brings about another discussion – that is, what aspects of QoL
are not affected by health or ill-health, especially when indirect influences are considered.
Chronic illness affects almost all aspects of life. Guyatt et al. (1993) asserted that “when
a patient is ill or diseased, almost all aspects of life can become health related”52.
Moreover, different diseases have different mechanisms of affecting QoL46. Therefore,
the recommended practice is to develop unique HRQoL questionnaires for different
diseases to uncover aspects of wellbeing most impacted by the particular health problem.
Evaluating the impacts of disease on a patient’s life is precisely the requisite for
“exploring the disease and illness experience” – one component of Stewart’s patientcentered clinical method34.
An evaluation of existing (HR)QoL questionnaires for AF found that most were adequate
at assessing physical functioning, symptoms, and psychological impacts (Chang J et al.,
unpublished data, May 2021). However, broader realms of wellbeing and life impacts
like social relationships, employment, and personal finances were overlooked. Most
questionnaires were developed for use in clinical trials instead of as a tool for routine use
in the clinic.
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2.4.2

Patient experience, PREMs, and patient journey mapping

Patient-reported experience measures (PREMs) typically concern patients’ experiences
with practical aspects of healthcare services such as wait times and patient-provider
communication41,50. They evaluate the patient’s experience or satisfaction with a
particular clinical encounter (e.g., surgery or consultation) to improve healthcare
delivery53. The majority of PREMs do not explore the patient’s lived experiences and are
not designed to understand how a chronic disease may affect multiple aspects of an
individual’s life over an extensive period of time.
To our knowledge, the only PREM for AF was adapted from the National Health Service
Adult Inpatient Survey. It was used to assess patients’ experiences with the catheter
ablation procedures performed in England54.
Visit-based PREMs fragment the patient experience. In reality, patients receive care from
different groups and move across healthcare providers and institutions55. The result is
healthcare providers only seeing the component of care for which they are responsible,
and no single provider oversees all the steps in a patient’s journey. True clinical process
redesign and healthcare reform must recognize that “the patient is the only person who
sees the whole journey”55.
Another method to collect data directly from patients that overcomes the fragmentation of
experiences is process mapping of the patient journey.
The patient journey is a visual tool used to understand how the patient encounters and
interacts with a series of consecutive healthcare services or events53. McCarthy et al.
(2016) developed an integrated patient journey mapping tool that can be used to evaluate
management strategies for healthcare service reform53.
Employed for a slightly different purpose, Bolz-Johnson and colleagues (2020) used
patient journey mapping as a way for patients to share their expertise and experience
when studying a rare syndrome called “genturis syndromes”40. The genetic tumour risk
syndrome is difficult to diagnose and lacks effective preventative and therapeutic
interventions. Stages in their journey maps were based on inherent disease stages and the
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clinical pathway. Their goal was to identify the needs common to the patients at each
stage.
Similar to “genturis syndromes”, AF lacks effective preventative measures and can be
hard to diagnose. As discussed previously, diagnosis of asymptomatic and paroxysmal
AF is frequently delayed. Asymptomatic individuals may not present to the clinic until
complications occur, and standard diagnostic procedures (12-lead ECG or 24/48-hour
Holter monitoring) may not capture short-lasting and intermittent AF episodes right
away11,15,56. In addition, there is much variability in the presentation of symptoms. The
many uncertainties that AF patients and clinicians face, especially before a diagnosis is
made, render it a candidate disease for patient journey mapping.

2.5 Atrial fibrillation patient journey
Understanding the realities and circumstances of patients is crucial to patient-centered
care, will provide insight into the challenges from the patient’s perspective, and will
allow clinical decisions to be made in a narrative that makes sense to patients57. We
describe a Canada-wide qualitative study on the arrhythmia patient journey conducted by
Dr. Mary Runte, a patient-partner researcher.
The project “Mapping of the Arrhythmia Patient Journey”, funded by the Cardiac
Arrhythmia Network of Canada57, is Canada’s first in-depth, comprehensive, and patientreported record of the experiences living with arrhythmia. This study consisted of
individual interviews, focus groups, and patient journey mapping that solicited the patient
view of the economic, employment, social, emotional, and psychological impacts of
arrhythmias57. The study involved patients with various arrhythmia conditions not limited
to AF. Patients with confirmed cardiac arrhythmias were asked to create a map of their
journey and describe the effects of their arrhythmia from the onset of symptoms to
treatment and beyond. Trend lines were created to capture the changes in emotions, social
relationships, employment, and finances over the course of their journeys.
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Ten focus groups (91 participants) and 62 individual in-depth interviews were conducted
in eight Canadian cities since August 2018. The focus groups had participants from all
provinces except for Manitoba57.

2.6 Mapping questionnaire items to the patient journey
Using the data collected from “Mapping of the Arrhythmia Patient Journey”, we
conducted secondary research to evaluate whether existing PROMs, specifically
(HR)QoL questionnaires for AF patients, capture important themes that emerged from the
focus groups and journey maps (Chang J et al., unpublished data, May 2021).
We searched for (HR)QoL questionnaires because they approximately measure patientperceived wellbeing impacted by AF. PROMs that assess symptom severity were not of
interest, and there was only one PREM specific to AF that concerns the ablation
experience. We analyzed only the transcripts and journey maps of AF patients to identify
relevant concerns under each of the four themes (“Emotional”, “Social”,
“Employment/Schooling”, and “Financial”). The results of thematic analysis are
summarized below:
It was an emotional experience for patients, particularly women, to try to get a diagnosis
for AF. Female patients reported feeling dismissed and not taken seriously when
communicating their symptoms to physicians. When a diagnosis was finally confirmed,
female patients expressed feeling validated. The unpredictability of episodes and
symptoms left patients, regardless of gender, to experience negative emotions. These
included feelings of worry, anxiety, loneliness, sadness, and fear. Women’s emotional
experiences tended to be more negative than men’s.
Social support changed over the course of the patient’s journey. At the beginning of their
AF journey, patients typically isolated themselves from family and friends due to feelings
of embarrassment and feeling like a burden to others. Family and friends were most
supportive at this time.
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As patients became more comfortable with their condition following treatment, patients
began to open up and seek social engagement. However, friends and family had pulled
back as a result of caregiver fatigue.
AF also affected patients’ personal finances. For example, patients missed work and lost
potential income when they felt ill or had to attend a medical appointment. The latter was
especially a burden for patients who live in rural areas and need to frequent medical
centers. Patients with more severe disease may need to change careers or retire early,
significantly impacting their source of income.
For patients who continued to work, work performance and relationships with colleagues
can be affected by patients’ conditions. The impact of AF on patient’s employment and
schooling was worse if institutions were not supportive or accommodating.
We mapped the items of four HR(QoL) questionnaires developed for AF patients onto
the themes and subthemes presented above. This provided insight into whether existing
questionnaires were adequate or if a new questionnaire was warranted to measure the AF
impact in the Canadian population. We determined the latter be true. Our analysis of
existing (HR)QoL questionnaires found that most were heavily focused on symptoms and
physical functioning, including the ability to perform daily activities. Two questionnaires,
the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and the Atrial Fibrillation
Quality of Life (AFQoL), addressed the impact of AF on patient’s emotional wellbeing
and social life. However, not all emotional- and social-related concerns found in the
focus groups and journey maps were addressed. None of the four questionnaires
measured AF’s impact on patients’ occupation, livelihood, and finances (Chang J et al.,
unpublished data, May 2021).
A new questionnaire that comprehensively measures the life impacts of AF along the
patient journey may be beneficial for research, holistic assessments in the clinic, and for
evaluating patient progress and healthcare delivery.
The above-mentioned study was conducted as part of the qualitative phase of the mixed
methods exploratory design for questionnaire development (Chang J et al., unpublished
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data, May 2021). The quantitative phase, which concerns the development and initial
validation of a new questionnaire, is based upon the qualitative and will be described in
Chapter 3.

2.7 Conclusion
No PROM adequately captures the impact of AF on patients throughout the patient
journey from symptom onset to post-treatment. We propose developing a new
questionnaire that will comprehensively measure the AF impact, with an emphasis on the
diagnostic experience, available social support, employment, and finances.
In this thesis, we describe the development and initial validation of the new questionnaire
(MAP-AF) as well as the analyses of the questionnaire scores. This thesis is a
quantitative investigation of the AF impact connected to earlier qualitative research
through questionnaire development. The mixed methods exploratory design will allow us
to gain a more comprehensive understanding of the impact AF has on patients.

20

2.8 References
1.

Arrhythmia. National Heart, Lung, and Blood Institute.
https://www.nhlbi.nih.gov/healthtopics/arrhythmia#:~:text=An%20arrhythmia%20is%20a%20problem,the%20con
dition%20is%20called%20bradycardia. Accessed May 21, 2021

2.

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS. Eur
Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210.

3.

Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics2019 Update: A Report From the American Heart Association. Circulation.
2019;139(10):e56-e528. doi: 10.1161/cir.0000000000000659.

4.

Dilaveris PE, Kennedy HL. Silent atrial fibrillation: epidemiology, diagnosis, and
clinical impact. Clin Cardiol. 2017;40(6):413-418. doi:10.1002/clc.22667.

5.

Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence,
prognosis, quality of life, and management. J Interv Card Electrophysiol.
2000;4(2):369-382. doi: 10.1023/a:1009823001707.

6.

Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial
Fibrillation in the 21st Century. Circ Res. 2020;127(1):4-20.
doi:10.1161/CIRCRESAHA.120.316340.

7.

Jackson SL, Tong X, Yin X, George MG, Ritchey MD. Emergency Department,
Hospital Inpatient, and Mortality Burden of Atrial Fibrillation in the United
States, 2006 to 2014. Am J Cardiol. 2017;120(11):1966-1973. doi:
10.1016/j.amjcard.2017.08.017.

8.

McCallum CJ, Raja DC, Pathak RK. Atrial fibrillation: an update on
management. Aust Prescr. 2019;42(6):186-191. doi:
10.18773/austprescr.2019.067.

9.

Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial
fibrillation: The Task Force for the Management of Atrial Fibrillation of the
European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
doi: 10.1093/eurheartj/ehq278.

10.

Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients
with atrial fibrillation: Results from the Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;167(5):735742.e732. doi: 10.1016/j.ahj.2014.02.003.

11.

Gutierrez C, Blanchard DG. Diagnosis and Treatment of Atrial Fibrillation. Am
Fam Physician. 2016;94(6):442-452.
https://www.aafp.org/afp/2016/0915/p442.html. Accessed May 24, 2021.

21

12.

Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular
Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the
Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847-1948. doi:
10.1016/j.cjca.2020.09.001.

13.

Rienstra M, Lubitz SA, Mahida S, et al. Symptoms and functional status of
patients with atrial fibrillation: state of the art and future research opportunities.
Circulation. 2012;125(23):2933-2943.
doi:10.1161/CIRCULATIONAHA.111.069450.

14.

Kamel H, Lees KR, Lyden PD, et al. Delayed Detection of Atrial Fibrillation after
Ischemic Stroke. J Stroke Cerebrovasc Dis. 2009;18(6):453-457. doi:
10.1016/j.jstrokecerebrovasdis.2009.01.012.

15.

Savelieva I, Paquette M, Dorian P, Lüderitz B, Camm AJ. Quality of life in
patients with silent atrial fibrillation. Heart. 2001;85(2):216-217. doi:
10.1136/heart.85.2.216.

16.

Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of
life in patients with intermittent atrial fibrillation: implications for the assessment
of investigational therapy. J Am Coll Cardiol. 2000;36(4):1303-1309. doi:
10.1016/S0735-1097(00)00886-X.

17.

Schnabel RB, Pecen L, Ojeda FM, et al. Gender differences in clinical
presentation and 1-year outcomes in atrial fibrillation. Heart. 2017;103(13):1024.
doi: 10.1136/heartjnl-2016-310406.

18.

Westerman S, Wenger N. Gender Differences in Atrial Fibrillation: A Review of
Epidemiology, Management, and Outcomes. Curr Cardiol Rev. 2019;15(2):136144. doi: 10.2174/1573403X15666181205110624.

19.

Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in
presentation, treatment, and outcome of patients with atrial fibrillation in Europe:
a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol.
2007;49(5):572-577. doi: 10.1016/j.jacc.2006.10.047.

20.

Lee JM, Kim TH, Cha MJ, et al. Gender-related Differences in Management of
Nonvalvular Atrial Fibrillation in an Asian Population. Korean Circ J.
2018;48(6):519-528. doi: 10.4070/kcj.2017.0389.

21.

Piccini JP, Simon DN, Steinberg BA, et al. Differences in Clinical and Functional
Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the
ORBIT-AF Registry. JAMA Cardiol. 2016;1(3):282-291. doi:
10.1001/jamacardio.2016.0529.

22.

Aliot E, Botto GL, Crijns HJ, Kirchhof P. Quality of life in patients with atrial
fibrillation: how to assess it and how to improve it. Europace. 2014;16(6):787796. doi: 10.1093/europace/eut369.

22

23.

Andrade JG, Verma A, Mitchell LB, et al. 2018 Focused Update of the Canadian
Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can
J Cardiol. 2018;34(11):1371-1392. doi: 10.1016/j.cjca.2018.08.026.

24.

Kotecha D, Ahmed A, Calvert M, Lencioni M, Terwee CB, Lane DA. PatientReported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A
Systematic Review of Measurement Properties. Plos One. 2016;11(11). doi:
10.1371/journal.pone.0165790.

25.

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ.
Validation of Clinical Classification Schemes for Predicting StrokeResults From
the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870. doi:
10.1001/jama.285.22.2864.

26.

Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical
Risk Stratification for Predicting Stroke and Thromboembolism in Atrial
Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey
on Atrial Fibrillation. Chest. 2010;137(2):263-272. doi: 10.1378/chest.09-1584.

27.

Pison L, Potpara TS, Chen J, et al. Left atrial appendage closure–indications,
techniques, and outcomes: results of the European Heart Rhythm Association
Survey. EP Europace. 2015;17(4):642-646. doi: 10.1093/europace/euv069.

28.

Khan MN, Jaïs P, Cummings J, et al. Pulmonary-Vein Isolation for Atrial
Fibrillation in Patients with Heart Failure. N Engl J Med. 2008;359(17):17781785. doi: 10.1056/NEJMoa0708234

29.

Andrade JG, Deyell MW, Lee AYK, Macle L. Sex Differences in Atrial
Fibrillation. Can J Cardiol. 2018;34(4):429-436. doi: 10.1016/j.cjca.2017.11.022.

30.

Witty MC. Client-Centered Therapy. In: Kazantzis N, LĽAbate L, ed. Handbook
of Homework Assignments in Psychotherapy. Boston, MA: Springer; 2007: 35-50.
https://doi.org/10.1007/978-0-387-29681-4_3. Accessed May 25, 2021.

31.

Balint E. The possibilities of patient-centered medicine. Br J Gen Pract.
1969;17(82):269-276. https://bjgp.org/content/bjgp/17/82/269.full.pdf. Accessed
May 25, 2021.

32.

Balint M. The doctor, his patient and the illness. Lancet. 1955;265(6866):683688. doi: https://doi.org/10.1016/S0140-6736(55)91061-8.

33.

Hudon C, Fortin M, Haggerty JL, Lambert M, Poitras ME. Measuring patients'
perceptions of patient-centered care: a systematic review of tools for family
medicine. Ann Fam Med. 2011;9(2):155-164. doi: 10.1370/afm.1226.

34.

Stewart M, Brown JB, Weston W, McWhinney IR, McWilliam CL, Freeman T.
Patient-Centered Medicine: Transforming the Clinical Method. Boca Raton, FL:
Taylor & Francis Group; 2013.

23

35.

Mead N, Bower P. Patient-centredness: a conceptual framework and review of the
empirical literature. Soc Sci Med. 2000;51(7):1087-1110. doi: 10.1016/s02779536(00)00098-8.

36.

Curran J. The Doctor, his Patient and the Illness. Bmj. 2007;335(7626):941. doi:
10.1136/bmj.39384.467928.94.

37.

Institute of Medicine (US) Committee on Quality of Health Care in America.
Crossing the Quality Chasm: A New Health System for the 21st Century.
Washington, DC: National Academies Press (US); 2001.

38.

Epstein RM, Street RL. The Values and Value of Patient-Centered Care. Ann Fam
Med. 2011;9(2):100. doi: 10.1370/afm.1239.

39.

Jayadevappa R, Chhatre S. Patient Centered Care -A Conceptual Model and
Review of the State of the Art. The Open Health Services and Policy Journal.
2011;4. doi: 10.2174/1874924001104010015.

40.

Bolz-Johnson M, Meek J, Hoogerbrugge N. “Patient Journeys”: improving care
by patient involvement. Eur J Hum Genet. 2020;28(2):141-143. doi:
10.1038/s41431-019-0555-6.

41.

Patient-reported Indicator Surveys (PaRIS). OECD.
https://www.oecd.org/health/paris/. Accessed May 22, 2021.

42.

Patrick DL, Burke LB, Gwaltney CJ, et al. Content Validity—Establishing and
Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO)
Instruments for Medical Product Evaluation: ISPOR PRO Good Research
Practices Task Force Report: Part 2—Assessing Respondent Understanding.
Value Health. 2011;14(8):978-988. doi: 10.1016/j.jval.2011.06.013.

43.

Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity--establishing and
reporting the evidence in newly developed patient-reported outcomes (PRO)
instruments for medical product evaluation: ISPOR PRO good research practices
task force report: part 1--eliciting concepts for a new PRO instrument. Value
Health. 2011;14(8):967-977. doi: 10.1016/j.jval.2011.06.014.

44.

Mark DB. Assessing quality-of-life outcomes in cardiovascular clinical research.
Nat Rev Cardiol. 2016;13(5):286-308. doi: 10.1038/nrcardio.2016.10.

45.

Power M, Kuyken W, Orley J, et al. The World Health Organization Quality of
Life assessment (WHOQOL): Development and general psychometric properties.
Soc Sci Med. 1998;46(12):1569-1585. doi: 10.1016/s0277-9536(98)00009-4.

46.

Arnold R, Ranchor AV, Sanderman R, Kempen GI, Ormel J, Suurmeijer TP. The
relative contribution of domains of quality of life to overall quality of life for
different chronic diseases. Qual Life Res. 2004;13(5):883-896. doi:
10.1023/B:QURE.0000025599.74923.f2.

24

47.

Zhan L. Quality of life: conceptual and measurement issues. J Adv Nurs.
1992;17(7):795-800. doi: 10.1111/j.1365-2648.1992.tb02000.x.

48.

Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life:
What is the Difference? Pharmacoeconomics. 2016;34(7):645-649. doi:
10.1007/s40273-016-0389-9.

49.

Ebrahim S. Clinical and public health perspectives and applications of healthrelated quality of life measurement. Soc Sci Med. 1995;41(10):1383-1394. doi:
10.1016/0277-9536(95)00116-o.

50.

Cella D, Hahn EA, Jensen SE, et al. Patient-Reported Outcomes in Performance
Measurement. Research Triangle Park (NC): RTI Press; 2015.
https://www.ncbi.nlm.nih.gov/books/NBK424378/. Accessed May 22, 2021.

51.

Peasgood T, Brazier, J.E., Mukuria, C., Rowen, D. A conceptual comparison of
well-being measures used in the UK. UK: Policy Research Unit in Economic
Evaluation of Health & Care Interventions (EEPRU); 2014.
http://www.eepru.org.uk/wp-content/uploads/2017/11/eepru-report-a-conceptualcomparison-of-well-being-measures-sept-2014-026.pdf. Published September
2014. Accessed May 22, 2021.

52.

Guyatt GH, Feeny DH, Patrick DL. Measuring Health-Related Quality-of-Life.
Ann Intern Med. 1993;118(8):622-629. doi: 10.7326/0003-4819-118-8199304150-00009.

53.

McCarthy S, O’Raghallaigh P, Woodworth S, Lim YL, Kenny LC, Adam F. An
integrated patient journey mapping tool for embedding quality in healthcare
service reform. Journal of Decision Systems. 2016;25(sup1):354-368. doi:
10.1080/12460125.2016.1187394.

54.

Ezzat VA, Chew A, McCready JW, et al. Catheter ablation of atrial fibrillationpatient satisfaction from a single-center UK experience. J Interv Card
Electrophysiol. 2013;37(3):291-303. doi: 10.1007/s10840-012-9763-5.

55.

Ben-Tovim D, Lewis M, O'Connell T, McGrath K. Patient Journeys: The Process
of Clinical Redesign. Med J Aust. 2008;188:S14-17. doi: 10.5694/j.13265377.2008.tb01668.x.

56.

Chou PS, Ho BL, Chan YH, Wu MH, Hu HH, Chao AC. Delayed diagnosis of
atrial fibrillation after first-ever stroke increases recurrent stroke risk: a 5-year
nationwide follow-up study. Intern Med J. 2018;48(6):661-667. doi:
10.1111/imj.13686.

57.

Runte M. Mapping the Arrhythmia Patient Journey. Cardiac Arrhythmia Network
of Canada. https://canet-nce.ca/mapping-the-arrhythmia-patient-journey/.
Published 2018. Updated February 16, 2018. Accessed August 7, 2020.

25

Chapter 3

3

Development of the MAP-AF questionnaire

As discussed in Chapter 2, several insights emerged from analyzing the transcripts of
about 101 patients with atrial fibrillation who participated in the project “Mapping the
Arrhythmia Patient Journey” (Chang J et al., unpublished data, May 2021). AF was found
to impact the patients’ psychological well-being, social relationships, occupation, and
personal finances. Moreover, it was more difficult for female patients to get a diagnosis
for AF than males – women more frequently expressed feeling dismissed when
communicating their symptoms to physicians.
Existing patient-reported outcome measures do not adequately measure these concerns
brought forth by AF patients in the focus groups and interviews (Chang J et al.,
unpublished data, May 2021). Our goal was to develop a patient-reported questionnaire
that would capture these important missing concerns and apply this questionnaire to
confirm the qualitative findings and test hypotheses.
Chapter 3 summarizes the development of the Mapping the Impact of Atrial Fibrillation
(MAP-AF) questionnaire. The chapter encompasses both the methods and the results of
item generation, exploratory factor analysis, and item reduction. The final MAP-AF
questionnaire described in this chapter was then used to develop hypotheses and plan the
analyses described in Chapter 4.

3.1 Methods
3.1.1

Item generation and questionnaire design

The Mapping the Impact of Atrial Fibrillation (MAP-AF) was developed to measure the
multi-faceted life impacts of AF as experienced by Canadian patients.
Thirty-five items were written to reflect the themes and concerns emerged from the
transcripts of AF patients (see section 2.6 for a summary of the themes and concerns).
For example, there were items about the emotional struggles of getting a diagnosis, the
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effects of AF on social relationships, employment, and personal finances. Furthermore,
some items were tied to a specific phase in the patient journey timeline: symptomonset/pre-diagnosis phase, peri-diagnosis phase, or post-diagnosis phase. Other items
asked about general concerns and current wellbeing. The print version of the preliminary
35-item MAP-AF is available in Appendix A.
The relevance and wording of the items were discussed with a patient-partner researcher,
and the final candidate items were reviewed by the committee members – including a
methodologist and a clinician.
All items utilized a 7-point Likert response scale. For items 16 to 21, the response options
ranged from “not at all bothered” to “extremely bothered”; for the remaining items, the
response options ranged from “strongly disagree” to “strongly agree”. Except for the
reverse coded items, a higher position on the scale reflects a greater experienced impact
or a more negative patient experience.
Due to the coronavirus disease 2019 (COVID-19) pandemic, the preliminary 35-item
MAP-AF was administered via an online survey platform – Qualtrics. The Software-as-aService platform uses Transport Layer Security encryption for all transmitted Internet
data1. The study was approved by the Western University Health Sciences Research
Ethics Board (HSREB) and Lawson Research. The initial approval letters and the most
recent approval letter for amendments are available in Appendix B.
Using Qualtrics, we incorporated skip patterns into the questionnaire such that the
occupation-related questions (items 4, 8, 9, 10, 11, 12, 17, and 18) were displayed only
for participants who were currently working or worked while experiencing AF. In
addition, a non-applicable (N/A) option was available for items 16, 17, 18, 19, 20, 21, 33,
34, and 35.
On Qualtrics, a textbox was available for respondents to comment on additional concerns,
the questionnaire design, or the questionnaire-taking experience. The comments from
respondents were used to inform some of the strengths and limitations of our study,
which are discussed in Chapter 5.
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Table 1. A list of the 35 items from the MAP-AF questionnaire
Item1
Item2
Item3
Item4
Item5
Item6
Item7
Item8

It was challenging for me to get a diagnosis for atrial fibrillation
My doctor did not take my symptoms seriously. I felt dismissed
My family and friends were always there for me before I was diagnosed
My symptoms before diagnosis were interfering with my ability to do my job
My diagnosis proved that my concerns were real
It felt emotionally relieving to receive my diagnosis
I felt despaired after receiving my diagnosis
Because of my symptoms, I cannot continue to work like I used to. For example, I had to work
part time or retire early because of my atrial fibrillation

Item9 My symptoms negatively impacted my work performance
Item10 My condition negatively impacted the relationships I had with people at work
Item11 I had to change my career path because of my atrial fibrillation. For example, starting a new
business or foregoing advancement
Item12 My employer was supportive and accommodating with regards to my atrial fibrillation
Item13 Having atrial fibrillation prompted me to rethink my life goals
Item14 As time went on, my family and friends became less supportive. For example, my family and
friends expected me to be over it by now.
Item15 My atrial fibrillation affected my romantic life (dating life, relationship with partner)
Item16 The cost of ambulance services for emergencies related to my atrial fibrillation
Item17 Having to miss work (for example, taking a day off) when I experienced symptoms and felt
unwell
Item18 Taking a day off or using a vacation day to attend medical appointments and examinations
Item19 The costs related to my clinic visits. For example, travelling to medical centers for
appointments and paying for transportation, parking, and/or accommodations.
Item20
Item21
Item22
Item23
Item24
Item25
Item26
Item27
Item28
Item29
Item30
Item31
Item32
Item33
Item34
Item35

My ability to get insurance because this is a pre-existing condition.
The lifestyle changes that I had to make because of my atrial fibrillation
I felt satisfied with my social life
I received the social support or engagement that I need
I isolated or distanced myself from others
My family and friends did not want to be around me
I felt lonely
I worried that I would experience symptoms or episodes of atrial fibrillation again
I felt hopeless about my health
I felt optimistic about my future
I felt grateful
I felt depressed
I felt anxious
I was bothered by the cost of my atrial fibrillation (consider all costs)
I worried about my future finances because of the costs related to my atrial fibrillation
My atrial fibrillation continued to impact my work life
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3.1.2

Participant recruitment

We recruited patients with AF who had a pulmonary vein ablation at the London Health
Sciences Centre (LHSC).
Patients were eligible for our study if they were over the age of 18, had a pulmonary vein
ablation, and were able to understand and complete an online questionnaire in English.
The MAP-AF asks questions about concerns along the patient journey and assumes
patients were experiencing AF-related symptoms prior to their diagnoses. Incidentally
diagnosed individuals would not be suited to answer items 1 to 5. A general treated
population of AF patients would be able to look back on their experiences from
symptom-onset to post-treatment and provide an overview of the AF patient journey.
Pulmonary vein ablation (PVA) is the cornerstone for most AF ablation procedures and is
often pursued for patients who remain symptomatic after rate or rhythm medications2. By
recruiting PVA patients, we could better exclude asymptomatic patients, who are more
likely to be incidentally diagnosed.
Patients who were not fluent in English or not familiar with the technological
requirements of the study were still eligible if they could receive assistance from another
individual such as a family member.
For exploratory factor analysis, a minimum of 10 cases per item and an absolute
minimum of 300 cases are recommended3-6. For our 35-item MAP-AF, a sample size of
350 would meet both recommendations. From the clinical database at the LHSC, we used
non-probability sampling and identified 500 consecutive post-PVA patients eligible for
our study.
A member within the patient’s circle of care mailed out invitation letters introducing the
study and informing potential participants to expect a call from the research student.
Patients were told in the letter that they had no obligation to take the call. Within three
weeks of sending the letters, the student contacted all 500 patients via telephone and
explained the study details outlined in the letter of information. If patients were
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interested, they were asked to provide their email address to receive the letter of
information and a personalized link to the online questionnaire. The target sample size
was 350. A participant flowchart is included in Figure 2.
Recruitment began on January 15, 2021 and continued until March 7, 2021.

3.1.3

Data collection and management

The email addresses provided by interested participants were uploaded onto Qualtrics,
and personalized links were emailed to participants through Qualtric’s internal mailing
system.
Once the link was accessed, participants were presented with the letter of information, the
35-item MAP-AF, and a separate list of questions that collected demographic and clinical
information. Participants received a reminder email two weeks before the March 7th
deadline.
Implied consent was obtained from participants who submitted the online questionnaire.
The first and last names, phone numbers, and email addresses of consenting participants
were collected and stored in the master list, separate from the de-identified questionnaire
responses. The master list and de-identified data are linkable by a unique study ID. Both
files are password protected, encrypted, and stored on Western’s OneDrive (an
institutionally sanctioned cloud), with access restricted to the research team. As per the
protocol for Lawson Research Institute-affiliated studies, both files will be retained at
Western for 15 years and securely destroyed after.

3.1.4

Demographic and clinical variables

A separate list of questions preceding the 35-item MAP-AF collected demographic and
clinical information from patients (Appendix C).
Textboxes were provided for participants to indicate their age and identified gender.
During data cleaning, age was recorded as the participant’s current age in years as of
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2021. Only two genders emerged in our sample (males and females); hence gender was
treated as a binary variable in subsequent analyses.
Four Yes/No questions related to participants’ employment were used to create a new
variable called work status that categorized participants into three groups:
I. Currently working
II. Not currently working, but previously worked while experiencing AF
III. Never worked or never worked while experiencing AF
The remaining demographic variables were categorical and included racial/ethnic
background, marital status, urban or rural residence, and educational attainment.
Five variables described the clinical characteristics of the sample: time of AF diagnosis,
type of AF (paroxysmal or persistent), frequency of AF episode (i.e., irregular heart
rhythm), time of last AF episode, and recent symptom severity. An additional question
made possible using the online survey platform was a graphic representing a timeline of a
patient journey that participants could click on, shown in Figure 1. A heatmap can then
be generated, visualizing where participants perceived themselves to be on their AF
journey.

Figure 1. Patient journey timeline graphic
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3.1.5

Descriptive analyses and data cleaning

The only continuous variable, age, was summarized using the mean (standard deviation)
and median (interquartile range). All other demographic and clinical variables were
categorical and were summarized using frequencies and percentages.
The literature review found gender differences in AF – women were more symptomatic
than men, but less likely to receive an ablation6,7. We used bivariate analyses to compare
the demographic and clinical characteristics of our male and female patients. Student’s
independent t-test was used to determine whether age differed significantly between the
two genders; Fisher’s exact test was used to determine whether there was an association
between the other categorical variables and gender. We excluded missing values in both
univariate and bivariate analyses.
The 35 item variables were assumed to be continuous from using a 7-point Likert
response scale. We described for each item the number of participants who skipped,
selected N/A, or did not provide a response. We also explored the missing patterns of the
items. Summary statistics were then provided for the complete cases.

3.1.6

Statistical analyses

All statistical analyses were performed using SAS software version 9.4 (Copyright ©
2016 by SAS Institute Inc., Cary, NC, USA)8.

3.1.6.1

Exploratory factor analysis

Factor analysis is a statistical technique used to explain a large set of observed variables
(e.g., items) using a smaller number of latent variables called factors9,10. Exploratory
factor analysis (EFA) allows items to freely load on factors. It is appropriate for
determining the underlying dimensions of newly developed questionnaires. Once strong
hypotheses about the factor structure exist, confirmatory factor analysis can be used to
test if the items load on hypothesized factors in a new sample9.We first investigated the
factorability of our data matrix by running a principal components analysis. We
examined the correlation matrix, partial correlation matrix, and Kaiser’s Measure of
Sampling Adequacy (MSA) for evidence of factors underlying the items. We then ran a
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preliminary factor analysis to check if the squared multiple correlations (SMCs) were
distant from 1, indicating an absence of singularity and multicollinearity11.
We determined the number of factors to extract using four criteria. In addition to
conventional criteria such as the eigenvalue-greater-than-1 rule (also known as Kaiser’s
criterion) and the scree plot, we performed parallel analysis and examined the minimum
average partial, both considered more accurate than the former methods12. Sensitivity
analyses were conducted to assess whether the suggested number of factors to extract
differed when log transformations of skewed items were performed or when using an
imputed dataset (using an expectation maximization algorithm to compute the maximum
likelihood estimates for missing data)13.
After several possible numbers of factors were identified, a series of factor analyses were
carried out using unweighted least squares extraction and promax rotation. Unweighted
least squares (ULS) is an extraction method robust to non-normal distributions, and
promax rotation is a type of oblique rotation which assumes some correlation between the
factors12,14,15. In contrast, orthogonal rotation methods assume factors are uncorrelated.
A series of sensitivity analyses was conducted to ensure the robustness of the final factor
structure to missing values, skewed items, and various extraction and rotation methods.

3.1.6.2

Item reduction and internal consistency

An item was said to load on a factor if the rotated factor loading from the pattern matrix
was greater or equal to 0.35. Once the items were grouped into factors, the internal
consistency of each factor was assessed using Cronbach's alpha. Irrelevant items were
identified as those with a low item-to-total correlation and high alpha-if-deleted values.
Redundant items were removed one at a time, with Cronbach's alpha recalculated upon
each deletion. Item reduction ceased when any further deletions would greatly decrease
the overall internal consistency of a factor. An EFA was repeated without the deleted
items to confirm the factor structure.
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3.1.6.3

Inter-factor correlation

We assessed the correlation between the identified factors to see whether they seem to be
measuring the same construct (i.e., the impact of AF as experienced by patients).

3.2 Results
3.2.1

Sample characteristics

Of the 319 individuals who agreed to be emailed the letter of information and the
questionnaire link, 277 individuals returned the questionnaire online – a response rate of
87%. A participant flowchart is included in Figure 2.
The mean (SD) age of participants was 63.8 (8.9) years. Age ranged from 26 years to 93
years. Since the distribution of age was slightly skewed as a result of a few younger
individuals, we also report the median and interquartile range of age. The median age for
male patients (n=193) was 64 years with an interquartile range of 59 to 70 years; the
median age for female patients (n=84) was 66 years with an interquartile range of 61 to
70 years.
Table 2 presents the demographic characteristics of male and female participants, and
Table 3 presents the clinical characteristics. Overall, the majority of participants were
white (95%), married (75%), diagnosed with AF more than three years ago (84%), and
were unsure of their AF type (paroxysmal or persistent) (55%).
Three individuals identified themselves as Métis, First Nations, Inuit, or other Indigenous
ancestries; three as Middle Eastern; and one as Asian (to avoid identifying patients, these
race/ethnicity categories were grouped with the “other” category in Table 2). Participants
who selected “other” (n=7) for racial and ethnic background identified themselves as
Scandinavian, Greek, French Canadian, Native and White, and Dutch. A quarter of all
participants were not married, of which half were divorced or separated, and another half
widowed or never married. Regarding educational attainment, 28% of participants had a
high school diploma or below, 35% had a college diploma or an apprenticeship or trade
certificate, and 38% had completed some university or had a bachelor’s degree or higher.
In terms of work status, 41% were currently working, 38% previously worked while
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experiencing AF, and 21% never worked or never worked while experiencing AF (Table
2). There were no students in our sample.

Figure 2. Participant flowchart
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Table 2. Demographic characteristics of 277 participants by gender
Characteristic
Age
(yr), mean (SD)
(yr), median (IQR)
Race/ethnicity, n (%)
White
Other
Marital status, n (%)
Married
Widowed
Divorced
Separated
Never Married
Education attainment, n (%)
High school diploma or below
College diploma or apprenticeship/trade
certificate
University below a bachelor’s degree
Bachelor’s degree or higher
Residence, n (%)
Urban
Suburban
Rural
Work status, n (%)
Currently working
Previously worked while experiencing AF
Never worked, or never worked while
experiencing AF

Male
N = 193

Female
N = 84

P-value

63.0 (9.3)
64.0 [59-70]

65.5 (7.7)
66.0 [61-70]

0.03a
0.50b

185 (96%)
8 (4%)

78 (93%)
6 (7%)
0.003b

156 (81%)
8 (4%)
16 (8%)
4 (2%)
9 (5%)

53 (63%)
13 (15%)
7 (8%)
6 (7%)
4 (5%)
0.046b

48 (25%)
72 (37%)

30 (36%)
25 (30%)

6 (3%)
67 (35%)

7 (8%)
22 (26%)
0.33b

81 (42%)
66 (34%)
46 (24%)

38 (45%)
21 (25%)
24 (29%)
0.02b

86 (45%)
74 (38%)
31 (16%)

27 (32%)
31 (37%)
26 (31%)

Student’s t test (equal variance assumption)
Fisher’s exact test
AF = atrial fibrillation; IQR = interquartile range; SD = standard deviation
Tabled frequencies may not add up to the total sample of 277 due to the omission of missing
values
P-values less than 0.05 are considered statistically significant and are bolded
Percentages may not add up to 100% due to rounding
a

b
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Table 3. Clinical characteristics of 277 participants by gender
Characteristic

Male
N = 193

Female
N = 84

Time of AF diagnosis, n (%)
Under 6 months ago
6 months to under 1 year ago
1 year to under 3 years ago
3 years to under 5 years ago
5 years ago, or more than 5 years ago

1 (0.5%)
1 (0.5%)
28 (15%)
50 (26%)
112 (58%)

0 (0%)
0 (0%)
14 (17%)
22 (26%)
48 (57%)

Type of AF, n (%)
Paroxysmal
Persistent
Unsure

53 (27%)
28 (15%)
110 (57%)

30 (36%)
12 (14%)
42 (50%)

Frequency of AF (irregular heart rhythm) episode, n (%)
Less than once a year
Once or a few times a year
Once or a few times a month
Once or a few times a week
Daily or constantly

52 (27%)
47 (24%)
30 (16%)
23 (12%)
32 (17%)

15 (18%)
13 (15%)
23 (27%)
11 (13%)
18 (21%)

Time of last AF episode, n (%)
Today or now
Within the past month
1 month to under 6 months ago
6 months to under 1 year ago
More than 1 year ago

8 (4%)
33 (17%)
29 (15%)
36 (19%)
87 (45%)

12 (14%)
21 (25%)
9 (11%)
14 (17%)
27 (32%)

Symptom severity as of recently, n (%)
Minimal to no symptoms
Mild symptoms
Moderate symptoms
Severe symptoms

92 (48%)
41 (21%)
35 (18%)
21 (11%)

25 (30%)
25 (30%)
20 (24%)
14 (17%)

P-value*
0.96

0.40

0.06

0.01

0.03

*P-values were computed using Fisher’s exact test
AF = atrial fibrillation
Tabled frequencies may not add up to the total sample of 277 due to the omission of missing
values
P-values less than 0.05 are considered statistically significant and are bolded
Percentages may not add up to 100% due to rounding
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Two-hundred and thirty-two individuals (84%) were diagnosed with AF more than three
years ago, of whom 69% were diagnosed more than five years ago (Table 3). Only two
individuals were diagnosed under a year ago. Slightly over half of the total sample did
not know whether they had paroxysmal or persistent AF. Of patients who knew, 83 had
paroxysmal AF and 40 had persistent AF. Patients in our study have had a pulmonary
vein ablation procedure, and most perceived themselves to be at the “treatment and
beyond” phase on a patient journey timeline (Figure 3). Many patients no longer
experienced AF following successful ablations – the current AF burden in our sample
was suspected to be moderate to low. In support of this, 41% last experienced an episode
of AF (irregular heart rhythm) more than a year ago, and 42% indicated minimal to no
recent symptoms (Table 3). Despite the reported percentages, we anticipate substantial
measurement error in three clinical variables. Questions asking about the frequency of
AF episodes, the time of last episode, and symptom severity were confusing to patients
who no longer experienced AF. Instead of reflecting on their current AF burden, some of
the patients responded in a way that reflected their past AF burden when they still had
AF. Consequently, present-day AF frequency and symptom severity were likely
overestimated. This is discussed in the limitations section in Chapter 5.

Figure 3. Heatmap visualization of the most prevalent phase
Bivariate analyses (Student’s t-test and Fisher’s exact tests) revealed statistically
significant gender differences in the following variables: age, marital status, educational
attainment, work status, time of last AF episode, and recent symptom severity. Compared
to male patients, females in our sample were more likely to be older, less likely to be in
marriage, less likely to have a bachelor’s degree or higher, less likely to have worked or
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be working, more likely to have experienced an AF episode recently, and more likely to
have severe symptoms.

3.2.2

Item characteristics

The number of respondents who answered, skipped, missed, or selected the N/A option
for each item is summarized in Table 4. Fifty-seven respondents automatically skipped
the eight work-related items (items 4, 8, 9, 10, 11, 12, 17, and 18) because they never
worked or never worked while experiencing AF. Alternatively stated, the work-related
items did not apply to 21% of the sample. Whenever a N/A option was available (i.e.,
items 16, 17, 18, 19, 20, 21, 33, 34, and 35), it was always selected by at least some
individuals.
Both the skip pattern and the incorporation of a N/A option were features of the
questionnaire designed to reflect the non-applicability of certain items. The eleven items
(marked by an asterisk in Table 4) that were considered non-applicable to greater than
10% of the total sample were removed from subsequent analyses. The remaining 24 items
proceeded to factor analysis.
Our data had few missing values, ranging from none to a maximum of 6 missing values
for item 12. A greater number of missing values were found for items without a N/A
option, suggesting that respondents may have missed an item because the statement was
not applicable, rather than simply missing by accident. Indeed, participants who had
missing values often selected the N/A option when possible and appropriate. We propose
that missing values could be attributed to suboptimal question wording, the nearby
presence of family members, forgetfulness, or the lack of a N/A option when the question
did not apply. We believe the last to be a probable explanation based on comments
provided by several patients. We discuss this in greater detail in Chapter 5.
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Table 4. The number of observed, non-applicable, skipped, and missing responses
Item

N

N/A

Skipped

Missing

1
2
3
4*
5
6
7
8*
9*
10*
11*
12*
13
14
15
16*
17*
18*
19
20*
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35*

276
275
275
219
276
275
275
218
219
216
218
213
276
275
275
177
177
188
260
230
263
276
273
276
273
275
276
276
276
273
274
273
252
252
239

99
41
30
16
45
13
24
24
36

57
57
57
57
57
57
57
57
-

0
1
1
0
0
1
1
1
0
3
1
6
0
1
1
0
1
1
0
1
0
0
3
0
3
1
0
0
0
3
2
3
0
0
1

Skip patterns only available for items 4, 8, 9, 10, 11, 12, 17 and 18.
Non-applicable responses only available for items 16, 17, 18, 19, 20, 21, 33, 34 and
35.
*Greater than 10% of all participants skipped the item or selected the N/A option
Total number of observations sums up to 276 after removing one observation that
did not belong to the target population
N = number of non-missing observations; N/A = non-applicable responses
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Investigation of the missing pattern identified one respondent who missed items 1 to 3
consecutively. The respondent indicated in the textbox that they could not answer the
questions because they experienced no symptoms before being diagnosed. Since we
determined incidentally diagnosed patients to be out of our target population, we
excluded this observation from subsequent analyses, reducing the total sample size from
277 to 276 (Figure 2).
The summary statistics of the 24 items using 276 observations are presented in Table 5.
The means ranged from 1.7 for item 25 to 5.9 for item 5. Four items (3, 5, 23, and 25)
had a large absolute skewness or kurtosis statistic, indicating departure from normality.
Item 25 was the most severely skewed, with a skewness of 2.5 and a kurtosis of 6.8. Log
transformations of the four items showed improvement only for item 25.

41

Table 5. Summary statistics of the 24 items for factor analysis
Item
1
2
3
5
6
7
13
14
15
19
21
22
23
24
25
26
27
28
29
30
31
32
33
34

N
276
275
275
276
275
275
276
275
275
260
263
276
273
276
273
275
276
276
276
273
274
273
252
252

N/A

Missing

16
13
24
24

0
1
1
0
1
1
0
1
1
0
0
0
3
0
3
1
0
0
0
3
2
3
0
0

For complete cases
Mean ± SD
Skewness
3.12 ± 2.04
2.44 ± 1.81
5.61 ± 1.65
5.88 ± 1.39
5.03 ± 1.67
4.11 ± 1.82
4.54 ± 1.76
2.47 ± 1.63
3.58 ± 2.06
2.47 ± 1.59
4.17 ± 1.98
5.20 ± 1.61
5.40 ± 1.36
2.96 ± 1.91
1.69 ± 1.17
2.55 ± 1.79
4.78 ± 2.00
3.21 ± 1.81
5.01 ± 1.51
5.45 ± 1.41
3.12 ± 1.90
3.97 ± 1.94
2.71 ± 1.83
2.67 ± 1.83

0.63
1.17
-1.46
-1.89
-0.81
-0.22
-0.42
1.10
0.17
1.02
0.04
-1.08
-1.15
0.68
2.46
1.02
-0.71
0.35
-0.87
-1.00
0.52
-0.17
0.91
1.01

Kurtosis
-1.01
0.12
1.38
3.74
-0.03
-1.01
-0.87
0.29
-1.45
0.38
-1.17
0.40
1.11
-0.92
6.77
-0.21
-0.78
-1.10
0.10
0.52
-1.06
-1.29
-0.47
-0.14

All items utilized a 7-point Likert scale and have not been reverse scored.
The lowest value, 1, corresponds to either “strongly disagree” or “not at all bothered”. The highest value,
7, corresponds to either “strongly agree” or “extremely bothered”.
N = number of non-missing observations; N/A = non-applicable responses; SD = standard deviation

3.2.3

Exploratory factor analysis

From the initial principal components analysis with varimax rotation, Kaiser’s Measure
of Sampling Adequacy (MSA) was 0.83, implying the presence of some factors that are
underlying and explaining the correlations between items11. The SMCs were also
sufficiently distant from 1, suggesting our data matrix to be absent from singularity and
multicollinearity.
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Before factor extraction and rotation, individuals who selected the N/A option for any of
the 24 items were excluded. This resulted in 239 analyzable responses, of which 229 had
no missing values (Figure 2). In addition to the complete case dataset (n=229), we created
an imputed dataset using the expectation maximization (EM) algorithm – a type of
maximum likelihood estimation13.
Table 6 compares the suggested number of factors to extract from the four criteria across
the various datasets (complete cases, EM imputed, complete cases with log
transformation of item 25, and EM imputed with log transformation of item 25). Based
on these results, we explored a 5-factor solution, a 6-factor solution, and a 7-factor
solution (Appendix E, F, and G). The scree plots are available in Appendix D.
Table 6. The numbers of factors to extract as suggested by the four criteria under
various conditions
Criteria

CCA

CCA with log
transformation
of item 25

EM
imputation

Kaiser’s criterion

6

6

6

EM imputation
with log
transformation
of item 25
6

Scree plot

2 or 5 or 8

2 or 6

2 or 3 or 5 or 8

2 or 5 or 8

Parallel analysis
(α=0.025)

5

5

6

6

Minimum Average
Partial

4 or 5

3 or 4

4

4

The results were obtained using principal components extraction with varimax rotation
CCA = complete-case-analysis (n=229); EM = expectation maximization (a type of maximum likelihood
estimation)

For each of the three possible factor solutions, eight EFAs were conducted to explore the
robustness of the factor loadings to a different extraction method (i.e., iterative principal
axis factoring), imputation of missing values, and log transformation of a skewed item
(Appendix E, F, G). When the threshold of minimum factor loading was set to 0.35, all
eight conditions produced the same factor structure. The 6-factor solution was chosen for
best interpretability and parsimony.

43

Table 7 presents the rotated factor loadings from the pattern matrix of a 6-factor solution.
The solution used a complete case analysis (n=229), unweighted least squares extraction,
and promax rotation. There were no cross-loading items (items that load onto more than
one factor) when the minimum factor loading was required to be at least 0.35.

Table 7. Rotated factor loadings from a six-factor solution using ULS extraction and
promax rotation
Items
Factor 1
Factor 2
Factor 3
Factor 4
Factor 5
Factor 6
1
-0.02
0.10
0.03
0.03
0.84
0.11
2
0.05
0.01
-0.04
-0.05
0.77
0.02
3
0.08
0.28
-0.06
0.04
0.02
0.47
5
-0.01
-0.07
-0.04
0.07
0.03
0.58
6
-0.07
-0.06
0.09
-0.08
0.09
0.67
7
0.41
0.16
-0.01
0.34*
-0.06
-0.12
13
0.03
0.06
0.06
0.61
-0.08
0.13
14
-0.05
-0.20
-0.02
0.31
0.23
-0.23
15
-0.02
-0.18
-0.002
0.55
0.22
-0.001
19
0.09
-0.05
0.46
0.05
0.01
0.08
21
0.05
-0.03
0.08
0.56
-0.07
0.006
22
-0.10
0.80
0.008
0.03
0.14
-0.13
23
0.03
0.78
-0.02
0.15
-0.003
0.05
24
0.10
-0.53
-0.12
0.30
-0.05
-0.07
25
-0.17
-0.45
0.11
0.27
0.01
-0.002
26
0.20
-0.43
0.06
0.22
0.02
0.009
27
0.80
0.18
-0.04
0.09
-0.01
0.03
28
0.75
-0.07
0.04
0.14
0.006
0.03
29
-0.63
0.08
-0.13
0.16
-0.09
0.18
30
-0.41
0.27
0.004
0.15
-0.16
0.13
31
0.55
-0.34*
0.02
0.05
0.05
0.10
32
0.78
-0.08
-0.02
-0.03
-0.06
0.09
33
-0.02
0.02
0.96
0.005
-0.04
-0.002
34
0.03
-0.004
0.80
0.08
0.02
-0.05
Bolded factor loadings are equal to or greater than 0.35
*factor loadings above 0.32 but less than 0.35, indicating poor loading
The factor analysis was conducted using complete cases (n=229), unweighted least squares
extraction, and promax rotation.
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3.2.4

Item reduction and internal consistency

The internal consistency, measured using Cronbach’s alpha, of the unreduced factor
structure ranged from 0.6 for factor 6 to 0.86 for factor 1 (Table 8). Redundant items in a
factor were identified and removed sequentially. Items 7, 30, and 29 were deleted from
factor 1 in that order; item 25 was deleted from factor 2; item 7 was deleted from factor
4.
The internal consistency of the refined factors is presented in Table 9.
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Table 8. Initial internal consistency of the six factors as indicated by Cronbach’s alpha
Factor structure

Standardized item correlation
with total

Standardized alpha-if-deleted

Factor 1 (standardized α = 0.86)
Item 7 “I felt despaired after receiving my diagnosis”
Item 27 “I worried that I would experience symptoms or episodes of atrial fibrillation again”
Item 28 “I felt hopeless about my health”
Item 29 “I felt optimistic about my future”
Item 30 “I felt grateful”
Item 31 “I felt depressed”
Item 32 “I felt anxious”

0.36
0.62
0.79
0.64
0.51
0.72
0.72

0.87
0.84
0.81
0.83
0.85
0.82
0.82

Factor 2 (standardized α = 0.79)
Item 22 “I felt satisfied with my social life”
Item 23 “I received the social support or engagement that I need”
Item 24 “I isolated or distanced myself from others”
Item 25 “My family and friends did not want to be around me”
Item 26 “I felt lonely”

0.67
0.57
0.59
0.46
0.57

0.72
0.75
0.75
0.79
0.75

Factor 3 (standardized α = 0.81)
Item 19 “I was bothered by the costs related my clinic visits”
Item 33 “I was bothered by the cost of my atrial fibrillation”
Item 34 “I worried about my future finances because of the costs related to my atrial fibrillation”

0.50
0.77
0.72

0.89
0.62
0.67

Factor 4 (standardized α = 0.66)
Item 7 “I felt despaired after receiving my diagnosis”
Item 13 “Having atrial fibrillation prompted me to rethink my life goals”
Item 15 “My atrial fibrillation affected my romantic life (dating life, relationship with partner)”
Item 21 “I was bothered by the lifestyle changes that I had to make because of my atrial fibrillation”

0.30
0.48
0.45
0.53

0.68
0.56
0.58
0.52

Factor 5 (standardized α = 0.78)
Item 1 “It was challenging for me to get a diagnosis of atrial fibrillation”
Item 2 “My doctor did not take my symptoms seriously. I felt dismissed”

0.64
0.64

-

Factor 6 (standardized α = 0.60)
Item 3 “My family and friends were always there for me before I was diagnosed”
Item 5 “My diagnosis proved that my concerns were real”
Item 6 “It felt emotionally relieving to receive my diagnosis”

0.35
0.51
0.38

0.58
0.51
0.55
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Table 9. Final internal consistency of the six factors as indicated by Cronbach’s alpha
Factor structure

Standardized item
correlation with total

Standardized alpha-ifdeleted

Factor 1: AFFECT (standardized α = 0.87)
Item 27 “I worried that I would experience symptoms or episodes of atrial fibrillation again”
Item 28 “I felt hopeless about my health”
Item 31 “I felt depressed”
Item 32 “I felt anxious”

0.63
0.77
0.71
0.77

0.87
0.81
0.83
0.81

Factor 2: SOCIAL SUPPORT (standardized α = 0.80)
Item 22* “I felt satisfied with my social life”
Item 23* “I received the social support or engagement that I need”
Item 24 “I isolated or distanced myself from others”
Item 26 “I felt lonely”

0.69
0.60
0.57
0.57

0.70
0.75
0.76
0.76

Factor 3: FINANCIAL IMPACT (standardized α = 0.81)
Item 19 “I was bothered by the costs related my clinic visits”
Item 33 “I was bothered by the cost of my atrial fibrillation”
Item 34 “I worried about my future finances because of the costs related to my atrial fibrillation”

0.50
0.77
0.72

0.89
0.62
0.67

Factor 4: MAJOR LIFE EVENTS (standardized α = 0.68)
Item 13 “Having atrial fibrillation prompted me to rethink my life goals”
Item 15 “My atrial fibrillation affected my romantic life (dating life, relationship with partner)”
Item 21 “I was bothered by the lifestyle changes that I had to make because of my atrial fibrillation”

0.50
0.46
0.53

0.58
0.63
0.54

Factor 5: DIAGNOSTIC EXPERIENCE (standardized α = 0.78)
Item 1 “It was challenging for me to get a diagnosis of atrial fibrillation”
Item 2 “My doctor did not take my symptoms seriously. I felt dismissed”

0.64
0.64

-

Factor 6 (standardized α = 0.60)
Item 3 “My family and friends were always there for me before I was diagnosed”
Item 5 “My diagnosis proved that my concerns were real”
Item 6 “It felt emotionally relieving to receive my diagnosis”

0.35
0.51
0.38

0.58
0.51
0.55

A factor analysis was rerun after deleting items 7, 25, 29, and 30, confirming the structure presented above.
*reverse coded items
Factor 6 and its items were excluded from the final factor structure due low interpretability and the factor’s low correlation with other factors
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3.2.5

Inter-factor correlation

Last, we examined the pairwise correlation between the six factors, shown in Table 10.
Examining the inter-factor correlations identified factor 6 as problematic, for it had very
low correlations with the other five factors. Furthermore, the three items constituting
factor 6 seemed to be poorly related, making it difficult to ascribe meaning to the factor.
The decision was to remove factor 6 and its items from the final factor structure.
Table 10. Inter-factor correlations between the six factors after item reduction

Factor 1
AFFECT
Factor 2
SOCIAL
SUPPORT
Factor 3
FINANCIAL
IMPACT
Factor 4
MAJOR LIFE
EVENTS
Factor 5
DIAGNOSTIC
EXPERIENCE

Factor 6

Factor 1
AFFECT

Factor 2
SOCIAL
SUPPORT

Factor 3
FINANCIAL
IMPACT

Factor 4
MAJOR
LIFE
EVENTS

Factor 5
DIAGNOSTIC
EXPERIENCE

Factor 6

1.00

0.53

0.40

0.44

0.27

0.07

1.00

0.43

0.39

0.27

-0.15

1.00

0.41

0.26

-0.005

1.00

0.23

0.13

1.00

0.13

1.00

Factor 6 and its items were excluded from the final factor structure due low interpretability and the factor’s
low correlation with other factors
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3.2.6

Final factor structure

The final MAP-AF contains five factors underlying 16 items: “Affect” (measuring
feelings of anxiety, depression, hopelessness, and worries), “Diagnostic Experience”
(measuring patients’ perceived difficulty of getting a diagnosis), “Social Support”,
“Financial Impact”, and “Major Life Events” (Table 9). Two of the items from “Social
Support” (items 22 and 23) are reverse scored. A higher overall score on the MAP-AF,
calculated as the mean of all 16 items, indicates a greater experienced impact of AF or a
more negative patient experience.
Figure 4 illustrates the flow of items from the 35 candidate items to the final 16 in the
MAP-AF.
The next chapter describes the scoring algorithm and the analyses of the factor and
overall scores of the MAP-AF. Analyses include hypothesis testing and multivariable
linear regression.
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Figure 4. Item flowchart
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Chapter 4

4

Analyses of the MAP-AF scores

This chapter describes both the methods and results of the MAP-AF score analyses.
Computation of the factor scores and the overall score, including the handling of missing
data, is described. A priori hypotheses related to the factor scores are tested, and a
multivariable linear regression is run on the overall score to identify significant
predictors.

4.1 Methods
4.1.1

Factor scores

The MAP-AF has five factors underlying 16 items: “Affect” and “Social Support” each
has four items, “Financial Impact” and “Major Life Events” each has three items, and
“Diagnostic Experience” has two. The complete factor structure, including the specific
items, can be found in Table 9 of Chapter 3.
The N/A options available for items 19, 33, and 34 from “Financial Impact” and item 21
from “Major Life Events” complicate factor score computation, along with missing
values.
We first referred to the item-total correlations of the four items presented in Table 9 of
Chapter 3. A low standardized item-total correlation and a high standardized alpha-ifdeleted value signal an item that is less essential or potentially irrelevant for the particular
factor. When examining “Financial Impact”, item 19 had the lowest item-total
correlation, and when deleted, may increase the overall Cronbach’s alpha from 0.81 to
0.89. On the other hand, deleting either items 33 or 34 will reduce the overall Cronbach’s
alpha significantly to the 0.6 range. Therefore, individuals selecting N/A or missing item
19 could still have a meaningful “Financial Impact” score computed. For “Major Life
Events”, item 21 (with the N/A option) had the highest item-total correlation and, if
deleted, would reduce the overall Cronbach’s alpha from 0.68 to 0.54. Item 21 was
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deemed essential to the factor – individuals selecting N/A or missing item 21 could not
have a meaningful “Major Life Events” score.
The computation criteria for the factor scores are summarized in Table 11 in the results
section. For the two 3-item factors, only 1 item was allowed to be missing or N/A: item
19 for “Financial Impact” and items other than item 21 for “Major Life Events”. Since
“Diagnostic Experience” only had two items, both items must be non-missing for the
factor score to be computed. For “Affect” and “Social Support”, at least two items needed
to be non-missing for computation (50% of items should be non-missing).
If factor scores were computable, they were calculated as an arithmetic mean of the nonmissing (and applicable) items. For “Social Support”, items 22 and 23 were reverse
coded. The mean factor scores range from 1 to 7, where a higher score reflects a more
significant impact experienced by patients.
An overall MAP-AF score was also computed as an arithmetic mean of the 16 items – if
all factor scores were computable. The mean overall score was then rescaled to range
from 0 to 100, where a higher score similarly indicates a worse patient experience or a
greater experienced impact of AF.

4.1.2

Descriptive analysis

Factor scores were summarized statistically using mean ± SD and graphically using
histograms, boxplots, and normal quantile-quantile (Q-Q) plots.
Bivariate analyses were conducted to examine the relationship between the overall score
and the demographic and clinical covariates. The linear and monotonic relationships
between age and the overall score were examined using the Pearson product-moment
correlation and the Spearman rank-order correlation, respectively. The non-parametric
Wilcoxon rank-sum test (also known as the Mann-Whitney U test or the WilcoxonMann-Whitney test) was used to assess gender differences in the overall score. The nonparametric Kruskal-Wallis test was used for all other categorical covariates with more
than two levels.
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Non-parametric tests were selected over parametric tests because some subgroup scores
were heavily skewed. This means that if the scores were normally distributed, the
inferential statistics presented are more conservative.
All statistical analyses were performed using SAS software version 9.4 (Copyright ©
2016 by SAS Institute Inc., Cary, NC, USA)1.

4.1.3

Hypothesis testing

We generated seven a priori hypotheses for the five factors based on pre-existing
knowledge and results from our previous qualitative work (Chang J et al., unpublished
data, May 2021).
To recap our previous findings, women and patients with intermittent AF episodes had a
more difficult time trying to get a diagnosis. Patients residing in rural areas incurred
higher transportation costs and lost potential income when they had to miss work and
travel for clinical appointments. We also discovered a pattern in social support. Family
and friends were the most supportive proximally before and after patients were
diagnosed. During this time, many patients withdrew socially from family and friends
due to feelings of embarrassment and guilt. As patients felt more comfortable with their
condition over time, they began to seek social engagement. However, friends and
families had started to decrease their support as a result of caregiver fatigue.
Based on these findings, we hypothesized the following:
I) & II) Female patients and paroxysmal patients will score higher (i.e., worse) on
“Diagnostic Experience” compared to male patients and persistent AF patients,
respectively
III) Patients residing in rural areas will score higher on “Financial Impact”
compared to patients residing in urban areas
IV) Patients who were diagnosed more distantly in the past will score higher (i.e.,
worse) on “Social Support” than patients recently diagnosed
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Three additional hypotheses were generated based on what is known in the literature:
V) Women tend to have larger support networks than men2. We hypothesize
female patients to score lower (i.e., better) on “Social Support” compared to male
patients
VI) Women tend to be more emotionally expressive than men3 and generally
experience greater anxiety and depression4,5. We hypothesize our female patients
to score higher on “Affect” compared to male patients
VII) Patients with paroxysmal AF are more likely to experience palpitations than
patients with persistent AF6. Paroxysmal patients may experience greater anxiety
due to the on and off palpitations. We hypothesize patients with paroxysmal AF to
score higher on “Affect” than patients with persistent AF
Hypotheses related to gender differences were tested using the Wilcoxon rank-sum test.
The Kruskal-Wallis test was used for all other hypotheses which have categorical
covariates with more than two levels. If the overall Kruskal-Wallis test was statistically
significant (p-value < 0.05), pairwise comparisons were made using the Dwass, Steel,
Critchlow-Fligner (DSCF) method. The DSCF statistics and the associated two-sided pvalue are computed based on pairwise two-sample Wilcoxon comparisons7.

4.1.4

Using statistical regression to select predictors

By the end of Chapter 3, the MAP-AF was validated in one sample of PVA patients.
Inferential analyses will remain exploratory until the MAP-AF can establish its validity
across multiple samples.
For this reason, it was acceptable at our stage to select predictors based on statistical
grounds.
There are three main methods for predictor selection in statistical regression: backward
selection, forward selection, and stepwise selection.
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Backward selection begins with a full model and deletes variables with the least
significant F statistic one at a time until all variables in the model have F statistics at a
specified stay significance level8. Vittinghoff and colleagues (2012) suggest a liberal
criterion for deletion, removing only variables with p-values greater or equal to 0.29.
Each deletion (or addition, in forward selection) produces a new model, resulting in a
sequence of models once variable movement halts. Either the last model in the sequence
or the model with the best fit statistics is usually selected. The R-square statistic is one of
the most common model fit statistics. An alternative tool for optimal model selection is
Akaike’s information criterion (AIC). The AIC measures the difference between a given
model and the “true” underlying model and is a function of sample size, sum of squared
errors, and the number of parameters10. It was shown to be superior for selecting the most
optimal model in statistical regression10.
A major limitation of both forward and stepwise selection methods is that they begin with
a null model. The full model (with all predictors) may never emerge unless all candidate
predictors are deemed significant. To that end, Vittinghoff et al. (2012) recommend using
backward selection primarily and the other two methods for sensitivity analyses9.
To select demographic and clinical covariates for the overall MAP-AF score, we used
backward selection with a significance level for retaining predictors set at 0.20. Of all the
models produced from the sequential deletion of variables, the model with the smallest
AIC was selected.
Sensitivity analyses were carried out to compare results obtained from backward
selection (stay significance level = 0.20), forward selection (entry significance level =
0.50), and stepwise selection (entry significance level = 0.20 and stay significance level =
0.20).
Missing values were excluded by list-wise deletion.

4.1.5

Multivariable linear regression

Based on the results of statistical regression, the final linear regression model for the
overall score included age (and age-squared), gender, marital status, educational
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attainment, and time of last AF episode. Parameter estimates of the linear regression were
obtained using the generalized linear model (GLM) procedure in SAS software since the
regression (REG) procedure does not directly handle categorical predictors11.
Age was centered to make the intercept more interpretable, and a quadratic term for age
was added to improve the linearity of the continuous predictor with the overall score.

4.1.6

Model fit and diagnostics

To check model assumptions, we examined the normality of the residuals,
homoscedasticity, and the linearity of age (the only continuous predictor). The adjusted
coefficient of determination (adjusted R2) reflected the model fit, and the Difference in
Fits (DFFITS) was used to detect influential observations. The DFFITS statistic for an
observation quantifies the change in predicted values when that observation is deleted12.
We explored the robustness of the parameter estimates to potentially influential
observations by deleting observations with the largest DFFITS five at a time.

4.1.7

Additional models

Using the same five predictors included in the main linear regression model, we ran five
additional models for the five factor scores.
The factor scores were rescaled to range from 0 to 100 for better interpretability.
Significant findings are briefly summarized in the results section.

4.2 Results
4.2.1

Descriptive analysis

The number of observations, mean, and standard deviation of each factor score are
summarized in Table 11. Thirteen individuals selected “N/A” for item 21, and hence, the
mean score for “Major Life Events” was not computable for these individuals. Likewise,
26 individuals selected “N/A” for either item 33 or 34, reducing the number of “Financial
Impact” scores to 250. “Financial Impact” had the lowest mean score (2.6 ± 1.5), and
“Major Life Events” had the highest mean score (4.1 ± 1.5). The factors “Affect” and
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“Major Life Events” were approximately normally distributed, whereas the other three
were quite skewed. Only 244 individuals had a mean score for all five factors; thus, the
overall MAP-AF score was computable for 244 individuals. The overall score on a scale
of 0 to 100 had a mean of 37.8 (SD: 17.8) and ranged from 2.1 to 89.6. The distribution
was positively skewed with a short tail on the left and a long tail on the right (skewness:
0.54, kurtosis: -0.11).
Table 11. Factor score computation and subsets
Factors

Number of
computable
scores
276

Mean ± SD

Range
(Min, Max)

3.76 ± 1.61

1, 7

No more than 50% of
items are missing

Social Support

276

2.73 ± 1.32

1, 6.8

No more than 50% of
items are missing

Financial Impact

250

2.61 ± 1.50

1, 7

Items 33 and 34 are
applicable and nonmissing

Major Life Events

263

4.12 ± 1.49

1, 7

Item 21 is applicable
and non-missing.
Otherwise, one missing
value for item 13 or
item 15 is acceptable.

Diagnostic
Experience

275

2.78 ± 1.76

1, 7

Both items are nonmissing

Overall score

244

37.8 ± 17.8

2.1, 89.6

All factor scores are
computable

Affect

Criteria for
computation

Max = maximum; Min = minimum; SD = standard deviation

Bivariate analyses revealed the following covariates to be significantly associated with
the overall MAP-AF score: age, gender, marital status, educational attainment, frequency
of AF episode, time of last AF episode, and recent symptom severity (Tables 12 and 13).
Higher (i.e., worse) scores were found in patients who were younger, female, divorced or
separated, had lower educational attainment, more frequent and more recent episodes,
and more severe symptoms. Patients self-identified as Métis, First Nations, Inuit, or other
Indigenous ancestries had the highest overall score (59 ± 16), compared to White
individuals (37.4 ± 17.8) and Middle Eastern individuals (35.9 ± 11). Nevertheless, the
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differences in scores between patients of various racial and ethnic backgrounds were not
statistically significant (p-value: 0.11). Tables 12 and 13 present the summary statistics of
the overall score in each subgroup of the categorical covariates.
Table 12. Relationship between demographic covariates and the overall score
Characteristic (n)
Age

Overall score
Mean (SD)
Pearson’s r: -0.11
Spearman’s r: -0.16

P-value
0.08
0.01

Gender
Male (171)
Female (73)

35.9 (16.8)
42.1 (19.4)

0.04a

Race/ethnicity
White (232)
Middle Eastern (Egyptian, Lebanese, Iranian) (2)
Métis, First Nations, Inuit, or other Indigenous ancestry (3)
Other (5)

37.4 (17.8)
35.9 (11.0)
59.0 (15.9)
49.6 (10.0)

0.11b

Marital status
Married (180)
Divorced/Separated (30)
Widowed/Never Married (33)

35.0 (16.9)
50.0 (18.4)
42.3 (16.8)

0.0001b

Educational attainment
High school diploma or below (68)
College diploma or apprenticeship/trade certificate (87)
University below a bachelor’s degree (11)
Bachelor’s degree or higher (78)

40.9 (20.4)
39.9 (16.6)
43.7 (17.4)
31.8 (15.3)

0.004b

Residence
Urban (104)
Suburban (78)
Rural (61)

37.6 (18.4)
35.8 (16.9)
40.4 (17.8)

0.39b

Work status
Currently working (99)
Previously worked while experiencing AF (94)
Never worked, or never worked while experiencing AF (50)

38.3 (18.2)
38.3 (17.4)
35.8 (18.0)

0.67b

a

Two-sided p-value obtained from the two-sample Wilcoxon-Mann Whitney test
P-value obtained from the non-parametric Kruskal-Wallis test
P-values less than 0.05 are considered statistically significant and are bolded.
Observations with missing values are excluded from the analyses.
Cells of 1 are omitted to avoid patient identification
b
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Table 13. Relationship between clinical covariates and the overall score
Characteristic (n)

Overall score
Mean (SD)

P-value*

Time of AF diagnosis
1 year to under 3 years ago (34)
3 years to under 5 years ago (61)
5 years ago, or more than 5 years ago (146)

36.7 (21.5)
38.6 (17.8)
37.9 (17.0)

0.62

Type of AF
Paroxysmal (75)
Persistent (34)
Unsure (134)

35.7 (17.5)
36.3 (20.0)
39.3 (17.4)

0.18

Frequency of AF (irregular heart rhythm) episode
Less than once a year (58)
Once or a few times a year (55)
Once or a few times a month (47)
Once or a few times a week (31)
Daily or constantly (42)

31.6 (14.8)
34.5 (13.4)
43.3 (20.6)
44.1 (20.0)
38.3 (18.3)

0.008

Time of last AF episode
More than 1 year ago (96)
6 months to under 1 year ago (47)
1 month to under 6 months ago (37)
Within the past month (46)
Today or now (17)

34.5 (17.1)
35.0 (15.7)
34.5 (16.1)
46.8 (18.6)
47.0 (19.0)

0.0002

Symptom severity as of recently
Minimal to no symptoms (96)
Mild symptoms (60)
Moderate symptoms (52)
Severe symptoms (32)

31.1 (15.8)
41.2 (17.5)
42.6 (17.4)
43.1 (19.6)

<0.0001

* P-value obtained from the non-parametric Kruskal-Wallis test
P-values less than 0.05 are considered statistically significant and are bolded.
Observations with missing values are excluded from the analyses.

Since only the Spearman correlation coefficient (r: -0.16, p-value: 0.01), and not the
Pearson correlation coefficient (r: -0.11, p-value: 0.08), was significant for age, we
anticipate age to exhibit a non-linear but monotonic relationship with the overall score.
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4.2.2

Hypothesis testing

The results of all hypothesis tests are summarized in Tables 14, 15, 16, and 17.
Hypothesis I:
Female patients scored significantly higher on “Diagnostic Experience” than male
patients (difference in means: 0.66, two-sided p-value: 0.006). The null hypothesis of no
difference was rejected at α = 0.05 (Table 14).
Hypothesis II:
“Diagnostic Experience” mean scores were significantly different between patients with
paroxysmal AF, persistent AF, and patients who were unsure of their AF type (p-value:
0.02) (Table 14). Pairwise comparisons using the DSCF method found paroxysmal
patients to score significantly higher than persistent patients on “Diagnostic Experience
(two-sided p-value: 0.04).
Table 14. The effect of gender and AF type on “Diagnostic Experience”

a

Gender

Male
Female

82

3.24

1.91

Type of AF

N Obs

Diagnostic Experience Factor
Mean score
SD

Paroxysmal

83

2.86*

1.77

Persistent

39

2.22*,**

1.75

Unsure

151

2.88**

1.75

193

2.58

1.66
0.006a

two-sided p-value obtained from the non-parametric Wilcoxon-Mann Whitney test
p-value obtained from the non-parametric Kruskal-Wallis test
N Obs = Number of observations; SD = standard deviation
*,**
statistically significant pairwise comparisons as indicated by the DSCF method
b

P-value

0.02b
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Hypothesis III:
There was no difference in the “Financial Impact” mean scores across areas of residence
(p-value: 0.11). Patients residing in rural areas did not score differently on “Financial
Impact” than patients residing in urban or suburban areas (Table 15).
Table 15. The effect of residence on “Financial Impact”

Residence

N Obs

Financial Impact Factor
Mean score
SD

Urban

107

2.52

1.52

Suburban

79

2.48

1.44

Rural

63

2.91

1.53

P-value

0.11a

a

p-value obtained from the non-parametric Kruskal-Wallis test
N Obs = Number of observations; SD = standard deviation

Hypothesis IV:
When comparing the “Social Support” mean scores across the different levels of the
“time of AF diagnosis” variable, two levels were excluded because they only had one
observation each (“under 6 months ago” and “6 months to under 1 year ago”). The
remaining three levels analyzed were “1 year ago to under 3 years ago”, “3 years ago to
under 5 years ago”, and “5 years ago or more than 5 years ago”.
The mean scores of “Social Support” decreased as the time since diagnosis became
shorter. The highest score was found in patients diagnosed 5 years ago or earlier.
Nevertheless, the differences in scores between the three groups were not statistically
significant (p-value: 0.66) (Table 16).
Hypothesis V:
Contrary to our hypothesis, female patients scored higher on “Social Support” than male
patients. However, this difference was not statistically significant (p-value: 0.87) (Table
16).
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Table 16. The effect of gender and time of AF diagnosis on “Social Support”

Time of
diagnosis

Gender

N Obs
Male

193

Social Support Factor
Mean score
SD
2.71

P-value

1.29
0.87a

Female

83

2.77

1.39

1 to under 3 years ago

42

2.65

1.47

3 to under 5 years ago

72

2.71

1.35

5 years or more than 5
years ago

159

2.77

1.26

0.66b

a

two-sided p-value obtained from the non-parametric Wilcoxon-Mann Whitney test
p-value obtained from the non-parametric Kruskal-Wallis test
N Obs = Number of observations; SD = standard deviation
b

Hypothesis VI:
As hypothesized, female patients scored significantly higher on “Affect” than male
patients (difference in means: 0.54, p-value: 0.02) (Table 17).
Hypothesis VII:
There was no difference in the “Affect” mean scores between patients with paroxysmal
AF, persistent AF, and patients unsure of their AF type (p-value: 0.08) (Table 17).
Table 17. The effect of gender and AF type on “Affect”

a

Gender

Male
Female

83

4.14

1.64

Type of AF

N Obs

Affect Factor
Mean score
SD

Paroxysmal

83

3.51

1.64

Persistent

39

3.56

1.63

Unsure

152

3.97

1.57

193

3.60

1.58
0.02a

two-sided p-value obtained from the non-parametric Wilcoxon-Mann Whitney test
p-value obtained from the non-parametric Kruskal-Wallis test
N Obs = Number of observations; SD = standard deviation
b

P-value

0.08b
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4.2.3

Statistical regression

There were seven demographic covariates and five clinical covariates in our dataset.
Before specifying all covariates into backward statistical regression, we carefully
examined three clinical covariates: frequency of AF episode, time of last AF episode, and
recent symptom severity. These variables were designed to reflect participants’ current
AF burden. However, they were problematic for patients who no longer experience AF
following successful PVA. A few of those patients asked for clarification because they
were unsure whether to approach the questions as they would in the past when they still
had AF or as of now. We suspect that many patients in a similar situation may have
responded in a way that reflected past AF burden. When we examined the responses
participants provided, we discovered many incongruent answers that were variants of the
following:
Frequency of AF episode(s) was “every day”; time of last AF episode was “more
than 1 year ago”; recent severity of symptoms was “severe”.
Based on the conflicting answers, “frequency of AF episode” and “recent symptom
severity” were likely measured with substantial error. “Time of last AF episode” might
be, relatively, a more accurate indicator of patients’ current AF burden post-PVA.
As a result, all but the two problematic covariates were considered for statistical
regression, including age, gender, racial or ethnic background, marital status, educational
attainment, residence, work status, time of AF diagnosis, AF type, and time of last AF
episode.
Since age seemed to exhibit a non-linear but monotonic relationship with the overall
score, a quadratic term was added to the model to improve linearity.
Table 18 summarizes the predictor selection results from backward, forward, and
stepwise regression. The selected model with the smallest AIC statistic was the same for
all three methods. This model contained age, age squared (age2), marital status,
educational attainment, and time of last AF episode.
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Table 18. Model selection comparing three different statistical regression methods
Selection method

Selection summary

Backward
(stay significance level:
0.20)

Variables removed: Work status,
racial/ethnic background, AF
type, gender, time of AF
diagnosis, residence
Variables entered: Marital status,
time of last AF episode,
educational attainment, age, age2,
gender, residence, time of AF
diagnosis, AF type
Variables entered: marital status,
time of last AF episode,
educational attainment, age, age2

Forward
(entry significance level:
0.50)

Stepwise
(entry significance level:
0.20,
stay significance level:
0.20)

Model with the smallest
AIC
Age, age2, marital status,
educational attainment,
time of last AF episode
Age, age2, marital status,
educational attainment,
time of last AF episode
Age, age2, marital status,
educational attainment,
time of last AF episode

All predictors initially specified: age, age2, gender, racial/ethnic background, marital status, educational
attainment, residence, work status, time of AF diagnosis, AF type, time of last AF episode
Number of observations used: 237
AIC = Akaike’s information criterion

Gender was not selected as a predictor on statistical grounds. However, we included
gender in all regression models because it was our primary predictor of interest.

4.2.4

Multivariable linear regression

The multivariable linear regression model of the overall score included the following
predictors: age (centered), age2 (centered then squared), gender, marital status,
educational attainment, and time of last AF episode. The regression coefficients, pvalues, and 95% confidence intervals are presented in Table 19.
The intercept was interpreted as follows. The average MAP-AF score for a patient that is
male, 63.8 years old (the mean age), married, with a bachelor’s degree or higher, and last
experienced an AF episode more than 1 year ago is 29.8 on a scale from 0 to 100 (95%
CI: 25.1 to 34.4).
Age was non-linearly related to the overall MAP-AF score. The addition of a quadratic
term improved linearity, model fit, and even changed qualitative conclusions for marital
status and educational attainment. Indeed, both the linear and quadratic terms for age
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were statistically significant and essential to the model (p-value: 0.002, 0.008,
respectively).
Table 19. Multivariable linear regression of the overall score on four (or five)
predictors

Predictor
Intercept
Age (centered)
Age2 (centered then squared)
Gender
Male (Ref)
Female
Marital status
Married (Ref)
Widowed or never married
Divorced or separated
Highest education attained
Bachelor’s or higher (Ref)
Some university below Bachelor’s
College or trade or apprenticeship
High school or below
Time of last AF episode
More than 1 year ago (Ref)
6 months to under 1 year ago
1 to under 6 months ago
Within the past month
Today or now

β

Full model
(n=242)
Adjusted R2: 20%
P-value
95% CI

Omitting “time of last episode”
(n=243)
Adjusted R2: 15%
β
P-value
95% CI

29.8
-0.43
-0.02

<0.001
0.002
0.008

25.1, 34.4
-0.69, -0.16
-0.04, -0.01

31.7
-0.43
-0.02

<0.001
0.002
0.008

27.5, 35.8
-0.70, -0.16
-0.04, -0.01

3.18

0.18

-1.48, 7.85

5.01

0.04

0.29, 9.74

6.63
12.2

0.04
<0.001

0.17, 13.1
5.92, 18.6

6.81
13.0

0.04
<0.001

0.28, 13.3
6.53, 19.4

9.44
4.47
6.22

0.07
0.08
0.02

-0.95, 19.8
-0.58, 9.53
0.85, 11.6

8.20
5.13
5.91

0.13
0.05
0.04

-2.49, 18.9
-0.06, 10.3
0.38, 11.4

0.24
-0.87
10.1
11.6

0.93
0.78
<0.001
0.008

-5.50, 5.98
-7.03, 5.30
4.38, 15.8
3.00, 20.2

-

-

-

Missing values were excluded by list-wise deletion.
P-values less than 0.05 are considered statistically significant and are bolded
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref =
Reference group for categorical variables

With each one-year increase in age, the overall score decreased by 0.43 (95% CI: -0.69 to
-0.16), adjusting for all other covariates, at the point where age is 63.8 years. Past the
mean age, the overall score decreases at an increasingly quicker rate for older individuals.
In statistical terms, the adjusted regression coefficient for age decreases by 0.02 with
every one-year increase in age (95% CI: -0.04 to -0.01).
Compared to married individuals, individuals not in marriage had a significantly higher
overall score. Divorced or separated patients scored 12.2 points higher (p-value <0.001,
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95% CI: 5.9 to 18.6), and widowed or never-married patients scored 6.6 points higher
than married patients (p-value: 0.04, 95% CI: 0.2 to 13.1), both adjusting for age, gender,
educational attainment, and time of last AF episode.
Patients who completed high school or below scored 6.2 points higher than patients with
a bachelor’s degree or higher (p-value: 0.02, 95% CI: 0.9 to 11.6), adjusting for age,
gender, marital status, and time of last AF episode. Patients who attended university
(below a bachelor’s degree) or who completed college, trade, or an apprenticeship also
scored higher than patients with a bachelor’s degree or higher. However, these
differences were not statistically significant.
Patients who last experienced an AF episode within the past month scored 10.1 points
higher than those who last experienced an episode more than a year ago (p-value <0.001,
95% CI: 4.4 to 15.8), adjusting for covariates. Patients who were experiencing an episode
the day of completing the questionnaire scored 11.6 points higher than patients whose last
episode was more than a year ago (p-value: 0.008, 95% CI: 3.0 to 20.2), adjusting for
covariates.
In terms of gender differences, female patients, on average, scored 3.2 points higher than
male patients. However, this difference was not statistically significant after adjusting for
age, marital status, educational attainment, and time of last episode (p-value: 0.18, 95%
CI: -1.5 to 7.9).
Earlier in predictor selection (section 4.2.3), we determined “frequency of AF episode”
and “recent symptom severity” to be problematic covariates with likely substantial
measurement error. We assumed the variable “time of last AF episode” to be an accurate
indicator of the patients’ current AF burden. However, “episode” was vaguely defined on
the questionnaire as “irregular heart rhythm”, and what was considered an “episode” may
have varied considerably between patients. When we removed this clinical covariate from
the model, the qualitative conclusion for gender changed from non-significance to
statistically significant (β: 5.0, p-value: 0.04, 95% CI: 0.29 to 9.74). The qualitative
conclusions for other predictors remained the same. The regression coefficients, p-values,
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and 95% confidence intervals for the model omitting “time of last AF episode” are also
included in Table 19.

4.2.5

Model fit and diagnostics

The model with predictors age, age2, gender, marital status, educational attainment, and
time of last episode had an adjusted R2 of 20.4%. Unmeasured variables such as
comorbidities and the effectiveness of treatment (i.e., success of pulmonary vein ablation)
may account for a portion of the remaining 79.6% variance unexplained. Better
measurement of patients’ AF characteristics, using a validated scale, would likely
enhance the adjusted R2.
The majority of the residuals fell on the diagonal line of the normal Q-Q plot,
approximating a normal distribution. No evident funnel shape was found when plotting
the residuals against the predicted values. Hence, there was no evidence of
heteroscedasticity. The linearity between the overall score and the only continuous
predictor, age, was satisfied after including a quadratic term.
We manually checked observations with a large R studentized residual or a large Cook’s
D statistic and determined there were no errors in data entry and no observations with an
alarming response profile.
We show the changes to the point and interval estimates after sequentially removing
influential observations with large DFFITS in Table 20. Briefly, removing influential
observations altered the educational landscape of the sample, changing qualitative
conclusions for patients who completed college, trade, or apprenticeship and patients who
completed high school or below. In addition, the p-value for gender increased from 0.18
to 0.22 after omitting five influential observations, and furthered increased to 0.47 after
omitting ten observations. The adjusted R2 was highest in the model omitting ten
observations with the highest DFFITS statistics, at 22%.
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Table 20. The effect of omitting influential (high DFFITS) observations on parameter estimates

Predictor
Intercept
Age (centered)
Age2 (centered then
squared)
Gender
Male (Ref)
Female
Marital status
Married (Ref)
Widowed or Never
married
Divorced or separated
Highest education
Bachelor’s or higher
(Ref)
Some university below
Bachelor’s
College or trade
High school or below
Last episode
More than 1 yr ago (Ref)
6 mo to 1 yr ago
1 to 6 mo ago
Within the past month
Today or now

β

All observations
(n = 242)
Adjusted R2 = 0.20
P-value
95% CI

Omitting five observations
(n = 237)
Adjusted R2 = 0.19
β
P-value
95% CI

Omitting ten observations
(n = 232)
Adjusted R2 = 0.22
β
P-value
95% CI

29.8
-0.43

<0.001
0.002

25.1, 34.4
-0.68, -0.16

30.0
-0.39

<0.001
0.004

25.6, 34.5
-0.64, -0.12

29.8
-0.45

<0.001
<0.001

25.5, 34.1
-0.70, -0.19

-0.02

0.008

-0.04, -0.01

-0.02

0.004

-0.04, -0.01

-0.03

<0.001

-0.04, -0.01

3.18

0.18

-1.48, 7.85

2.87

0.22

-1.69, 7.43

1.62

0.47

-2.83, 6.07

-

-

-

-

-

-

-

-

-

6.63

0.04

0.17, 13.1

6.90

0.03

0.56, 13.2

7.22

0.02

1.0, 13.4

12.2

<0.001

5.92, 18.6

9.98

0.002

3.73, 16.2

10.8

<0.001

4.79, 16.8

-

-

-

-

-

-

-

-

-

9.44

0.07

-0.95, 19.8

5.98

0.26

-4.43, 16.4

7.48

0.14

-2.55, 17.5

4.47
6.22

0.08
0.02

-0.58, 9.53
0.85, 11.6

4.38
4.82

0.08
0.07

-0.50, 9.27
-0.38, 10.0

4.87
5.43

0.04
0.04

0.11, 9.63
0.36, 10.5

0.24
-0.87
10.1
11.6

0.93
0.78
<0.001
0.008

-5.50, 5.98
-7.03, 5.30
4.38, 15.8
3.0, 20.2

0.33
-1.05
11.0
10.6

0.91
0.73
<0.001
0.01

-5.23, 5.90
-7.06, 4.96
5.55, 16.5
2.13, 19.1

0.23
-1.64
9.85
11.7

0.93
0.58
<0.001
0.005

-5.16, 5.62
-7.47, 4.20
4.48, 15.2
3.50, 19.9

The initial dataset had 244 observations. Two observations had missing values and were thus excluded from the linear regression models. All ten outliers were
identified by the DFFITS statistic. The first five influential points with the largest DFFITS statistic were removed; and the next five were removed.
P-values less than 0.05 are considered statistically significant and are bolded.
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref = Reference group for categorical variables
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4.2.6

Additional models

Tables 21, 22, 23, 24, and 25 present the results from the additional models ran on the
five factor scores. All factor scores were rescaled to range from 0 to 100 points.
Major findings are briefly summarized below.
Female patients scored 8.6 points higher than male patients on “Diagnostic Experience”,
adjusting for age, marital status, educational attainment, and time of last AF episode (pvalue: 0.04, 95% CI: 0.5 to 16.7). Older patients scored lower on “Major Life Events”
and “Financial Impact” – a one-year increase in age resulted in a 0.5 point decrease in
“Major Life Events” (p-value 0.01, 95% CI: -0.90 to -0.10) and a 0.83 point decrease in
“Financial Impact” (p-value <0.001, 95% CI: -1.21 to -0.44), after adjustment.
Divorced or separated patients scored 10.7 points higher on “Affect” (p-value: 0.03, 95%
CI: 0.96 to 20.5), 21.1 points higher on “Social Support” (p-value <0.001, 95% CI: 13.4
to 28.9), 11.9 points higher on “Major Life Events” (p-value: 0.01, 95% CI: 2.6 to 21.3),
and 13.4 points higher on “Financial Impact” (p-value: 0.004, 95% CI: 4.4 to 22.3)
compared to married patients, adjusting for covariates.
Compared to patients last experiencing an AF episode more than a year ago, patients last
experiencing an episode within the past month scored 12.3 points higher on “Affect” (pvalue: 0.005, 95% CI: 3.8 to 20.9) and patients last experiencing an episode in the past
day scored 15.7 points higher on “Financial Impact” (p-value: 0.01, 95% CI: 3.3 to 28.1),
after adjusting for covariates. Moreover, compared to patients with a bachelor’s degree or
higher, patients with a high school education or below scored 11.5 points higher on
“Affect” (p-value: 0.006, 95% CI: 3.4 to 19.6) and 10 points higher on “Financial
Impact” (p-value: 0.01, 95% CI: 2.4 to 17.7), after adjustment.
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Table 21. Multivariable linear regression of Affect scores

Predictor

β

Affect
N = 274 Adjusted R2: 7.6%
P-value

95% CI

Intercept
32.9
<0.001
26.3, 39.5
Age (centered)
-0.03
0.86
-0.39, 0.33
Gender
Male (Ref)
Female
5.96
0.10
-1.20, 13.1
Marital status
Married (Ref)
Widowed or never married
4.53
0.38
-5.52, 14.6
Divorced or separated
10.7
0.03
0.96, 20.5
Highest education attained
Bachelor’s or higher (Ref)
Some university below Bachelor’s
6.96
0.38
-8.67, 22.6
College or trade or apprenticeship
8.69
0.03
1.03, 16.4
High school or below
11.5
0.006
3.35, 19.6
Time of last AF episode
More than 1 year ago (Ref)
6 months to under 1 year ago
0.05
0.99
-8.80, 8.91
1 to under 6 months ago
1.55
0.75
-8.19, 11.3
Within the past month
12.3
0.005
3.81, 20.9
Today or now
5.57
0.40
-7.44, 18.6
Missing values were excluded by list-wise deletion.
P-values less than 0.05 are considered statistically significant and are bolded
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref =
Reference group for categorical variables
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Table 22. Multivariable linear regression of Diagnostic Experience scores

Predictor

β

Diagnostic Experience
(n=273)
Adjusted R2: 2.6%
P-value
95% CI

Intercept
18.6
<0.001
11.1, 26.0
Age (centered)
-0.07
0.74
-0.47, 0.34
Gender
Male (Ref)
Female
8.61
0.04
0.54, 16.7
Marital status
Married (Ref)
Widowed or never married
4.61
0.42
-6.67, 15.9
Divorced or separated
4.74
0.40
-6.37, 15.8
Highest education attained
Bachelor’s or higher (Ref)
Some university below Bachelor’s
4.31
0.63
-13.2, 21.9
College or trade or apprenticeship
9.03
0.04
0.43, 17.6
High school or below
6.89
0.14
-2.24, 16.0
Time of last AF episode
More than 1 year ago (Ref)
6 months to under 1 year ago
2.74
0.59
-7.20, 12.7
1 to under 6 months ago
-1.56
0.78
-12.6, 9.46
Within the past month
5.53
0.26
-4.06, 15.1
Today or now
8.44
0.26
-6.19, 23.1
Missing values were excluded by list-wise deletion.
P-values less than 0.05 are considered statistically significant and are bolded
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref =
Reference group for categorical variables
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Table 23. Multivariable linear regression of Social Support scores

Predictor

β

Social Support
(n=274)
Adjusted R2: 13%
P-value

95% CI

Intercept
21.0
<0.001
15.7, 26.2
Age (centered)
-0.25
0.09
-0.54, 0.04
Gender
Male (Ref)
Female
-2.48
-0.39
-8.15, 3.20
Marital status
Married (Ref)
Widowed or never married
7.18
0.08
-0.78, 15.1
Divorced or separated
21.1
<0.001
13.4, 28.9
Highest education attained
Bachelor’s or higher (Ref)
Some university below Bachelor’s
13.7
0.03
1.34, 26.1
College or trade or apprenticeship
4.90
0.11
-1.17, 11.0
High school or below
5.99
0.07
-0.44, 12.4
Time of last AF episode
More than 1 year ago (Ref)
6 months to under 1 year ago
-2.07
0.56
-9.08, 4.94
1 to under 6 months ago
-1.24
0.75
-8.96, 6.47
Within the past month
5.68
0.10
-1.09, 12.4
Today or now
8.24
0.12
-2.07, 18.5
Missing values were excluded by list-wise deletion.
P-values less than 0.05 are considered statistically significant and are bolded
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref =
Reference group for categorical variables
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Table 24. Multivariable linear regression of Major Life Events scores

Predictor

β

Major Life Events
(n=261)
Adjusted R2: 4.1%
P-value

95% CI

Intercept
49.8
<0.001
43.0, 56.6
Age (centered)
-0.50
0.01
-0.90, -0.10
Age2 (centered then squared)
-0.03
0.02
-0.05, -0.01
Gender
Male (Ref)
Female
-1.59
0.65
-8.47, 5.28
Marital status
Married (Ref)
Widowed or never married
3.24
0.51
-6.51, 13.0
Divorced or separated
11.9
0.01
2.57, 21.3
Highest education attained
Bachelor’s or higher (Ref)
Some university below Bachelor’s
2.23
0.77
-12.6, 17.1
College or trade or apprenticeship
0.14
0.97
-7.30, 7.57
High school or below
-0.71
0.86
-8.66, 7.23
Time of last AF episode
More than 1 year ago (Ref)
6 months to under 1 year ago
3.51
0.41
-4.92, 11.9
1 to under 6 months ago
0.22
0.96
-9.02, 9.47
Within the past month
8.77
0.04
0.29, 17.2
Today or now
12.0
0.07
-0.86, 24.9
Missing values were excluded by list-wise deletion.
P-values less than 0.05 are considered statistically significant and are bolded
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref =
Reference group for categorical variables
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Table 25. Multivariable linear regression of Financial Impact scores

Predictor

β

Financial Impact
(n=248)
Adjusted R2: 16.9%
P-value

95% CI

Intercept
19.9
<0.001
13.4, 26.5
Age (centered)
-0.83
<0.001
-1.21, -0.44
Age2 (centered then squared)
-0.04
0.001
-0.06, -0.01
Gender
Male (Ref)
Female
4.93
0.14
-1.70, 11.6
Marital status
Married (Ref)
Widowed or never married
11.1
0.02
1.85, 20.4
Divorced or separated
13.4
0.004
4.42, 22.3
Highest education attained
Bachelor’s or higher (Ref)
Some university below Bachelor’s
1.95
0.80
-12.9, 16.8
College or trade or apprenticeship
2.91
0.42
-4.26, 10.1
High school or below
10.0
0.01
2.38, 17.7
Time of last AF episode
More than 1 year ago (Ref)
6 months to under 1 year ago
-1.96
0.64
-10.2, 6.27
1 to under 6 months ago
-2.29
0.61
-11.1, 6.48
Within the past month
5.85
0.15
-2.15, 13.8
Today or now
15.7
0.01
3.34, 28.1
Missing values were excluded by list-wise deletion.
P-values less than 0.05 are considered statistically significant and are bolded
AF = atrial fibrillation; β = regression coefficient; CI = confidence interval; R2 = coefficient of determination; Ref =
Reference group for categorical variables
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Chapter 5

5

Discussion and conclusion

The summary and interpretation of the results are presented in this chapter. These include
results from questionnaire development (Chapter 3) and analyses of the questionnaire
scores (Chapter 4). We will also discuss the implications of the results, the strengths, and
the limitations of this thesis. We conclude with suggestions for future research.

5.1 Summary of results
This thesis was built upon previous qualitative research. From focus groups with
arrhythmia patients in Canada, AF was found to impact patients’ mental wellbeing, social
relationships, livelihood, and finances. Existing (HR)QoL questionnaires do not
adequately measure the AF impact. Most questionnaires were developed to assess QoL
changes before and after treatment. Therefore, their primary focus is on physical
functioning, symptoms, ability to perform daily activities, and affect. This led to our
proposal to develop a new questionnaire to comprehensively understand the effects of AF
along the patient journey – covering broader life impacts and challenges surrounding
diagnosis (a central theme of the AF patient experience).

5.1.1
5.1.1.1

Results of questionnaire development
Construct of interest

HRQoL questionnaires typically take a snapshot of the patient’s physical functioning,
symptoms, and psychological wellbeing over a four-week period. Validated ones are
suitable for evaluating the effects of interventions during the treatment phase. Beyond
this need to evaluate treatment efficacy, there is little interest in understanding QoL
during symptom onset and how the disease affects multiple aspects of patients’
wellbeing. This is where the MAP-AF differs from existing instruments as a patientreported measure that addresses these gaps and recognizes the dynamics of the patient
journey. The most prominent concerns of patients fluctuate over the clinical course of
AF.
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While the MAP-AF can be considered a measure of patient outcomes, one domain
(“Diagnostic Experience”) is dedicated to measuring patients’ experiences with medical
care. The international PaRIS survey, developed for patients with chronic conditions,
similarly measures both important outcomes and experiences of health care in one
instrument1.
“Financial Impact” and “Social Support” are two domains of the MAP-AF that are
typically considered non-health-related. Although non-health-related aspects of wellbeing
are less likely to change due to medical interventions, they are nevertheless affected by
disease and experienced by patients. The LupusPRO questionnaire developed by Jolly et
al. (2012) measures both health-related and non-health-related aspects of QoL of
systemic lupus erythematosus patients2. A holistic understanding of the impact of disease
helps researchers and clinicians gain insight into patient needs and improve healthcare
services2.

5.1.1.2

Factor structure and internal consistency

After exploratory factor analysis and item reduction, the MAP-AF questionnaire had 16
items and five domains: “Affect”, “Social Support”, “Financial Impact”, “Major Life
Events”, and “Diagnostic Experience”. Considering we did not have a priori hypotheses
about the number of factors underlying the items, the factor solution came out
unexpectedly clean. Results of EFA can often be quite messy, conflicting, and difficult to
interpret, especially when sample sizes are small and loadings are weak3.
When the threshold factor loading was set to 0.35, there were very few cross-loading
items: two in the 5-factor solution, one in the 6-factor solution, and none in the 7-factor
solution. Furthermore, the same factor solutions emerged even under different data
conditions. The rotated factor loadings were robust to the factor extraction methods (ULS
vs. iPAF), rotation methods (promax vs. direct oblimin), missing value imputation (CCA
vs. EM), and log transformation of one skewed item (i.e., item 25). Based on parsimony
and interpretability, the 6-factor structure was initially chosen as the solution for further
scrutiny using measurement properties like the item-total correlation, Cronbach’s alpha,
and inter-factor correlation.
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The final MAP-AF had five domains because one factor (original factor 6) was deemed
problematic. The three items in the factor were difficult to interpret (i.e., does not appear
to reflect one unifying concept) and had low item-total correlations. The factor itself had
poor internal consistency (0.70 to 0.95 considered good internal consistency)4 and a low
correlation with the other five factors. We also failed to redistribute the three items to the
other established factors, ultimately resulting in our decision to remove the items from
the final questionnaire.
For the remaining five factors, all except for “Major Life Events” had good internal
consistency. The “Major Life Events” factor had a borderline Cronbach’s alpha of 0.68.
Despite having only two items, the “Diagnostic Experience” factor was stable and had a
high alpha of 0.78.
The result of EFA is sample-dependent, and one of the sample characteristics that may
affect EFA results is where patients are on the patient journey. Our study recruited
patients who had a pulmonary vein ablation – most patients in our sample identified
themselves to be in the treatment and beyond phase, and many were “cured”.
While our post-PVA sample provided us with an overview of the patient journey, we
recognize that the factor loadings and the factor structure of the MAP-AF may be
different had we used a different patient sample. For example, if we administered the 35item MAP-AF to a sample of recently diagnosed patients, the factor structure we obtain
may be quite different.

5.1.2
5.1.2.1

Results of questionnaire scores
Descriptive analyses of questionnaire scores

The overall MAP-AF scores were not high for our sample – the mean was 37.8 points out
of 100. Likewise, “Social Support”, “Financial Impact”, and “Diagnostic Experiences”
had mean scores less than 3 on a 7-point Likert scale. “Affect” had a mean score of 3.76,
and “Major Life Events” had the highest mean score of 4.12. The result is likely a
consequence of a sample composed of mostly “cured” patients who no longer experience
episodes and symptoms of AF. Over 80% of our patients were diagnosed more than three
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years ago, 41% last experienced an episode more than a year ago, and 42% experienced
minimal to no symptoms recently. The perceived impact of AF may be lesser for
individuals who no longer experience the condition than those who are actively
experiencing the disease.
During sample selection, we recruited only patients who had a pulmonary vein ablation.
Patients typically receive such a procedure if they remain symptomatic after rate and
rhythm medications. By recruiting PVA patients, we would reduce the inclusion of
asymptomatic patients, who are more likely to be incidentally diagnosed (and hence illsuited for answering diagnosis-related questions). Unfortunately, we were unable to
exclude all incidentally diagnosed individuals with this eligibility criteria. From patient
comments, we found that several were diagnosed when presented to the emergency
department for other reasons or during routine physical examinations. The inclusion of
these patients likely lowered the “Diagnostic Experiences” mean scores since they would
have selected “strongly disagree” for the items when in reality, the most suitable response
was “non-applicable”.

5.1.2.2

Multivariable linear regression of the overall score

The total score on the MAP-AF reflects the extent to which patients have been affected
by AF across all domains. Multivariable linear regression found age, marital status,
educational attainment, and time of last AF episode to be associated with the overall
score. Generally, patients were more impacted by AF if they were younger, divorced or
separated, had lower education, or experienced more recent episodes of AF. Randolph et
al. (2016) conducted similar analyses using the Atrial Fibrillation Effect on Quality of
Life (AFEQT) scale and found female sex, younger age, new-onset AF, higher heart rate,
and the presence of comorbidities to be significantly associated with a reduced QoL5.
Another study also found sex differences in QoL improvements over time, in which
female patients showed less improvement in AFEQT scores over 1 year than male
patients6.
Based on previous literature that found women to be more symptomatic yet less likely to
be offered an ablation, we hypothesized that there would be gender differences in the AF
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impact7,8. Contrary to our expectations and different from other QoL studies, gender was
not significantly correlated with the overall score in this study. Nevertheless, when time
of last AF episode was tentatively excluded from the model, the effect of gender became
significant (p-value went from 0.18 to 0.036). The qualitative conclusions for the other
covariates remained the same. We speculate that the effect of gender on AF impact was
likely confounded by disease severity and disease burden. Presumably, female patients
were more impacted by AF than male patients because they experienced more frequent
episodes and more severe symptoms even after pulmonary vein ablation. When disease
severity was accounted for using the variable “time of last episode”, gender was no
longer significant.
The four variables (age, marital status, educational attainment, and time of last AF
episode) explained 20.4% of the variance of the overall score. The remaining unexplained
variance could be attributed to comorbidities, treatment effectiveness, and other AF
characteristics. Future studies should include valid and accurate measurements of the
above variables (e.g., using validated scales to assess AF symptom severity).

5.1.2.3

Predictors

This section discusses the relationships between selected predictors and the five MAP-AF
domains based on the additional analyses.
First, our results supported previous research that found women to have a more difficult
time trying to get a diagnosis for AF. Scores on “Diagnostic Experience” were higher for
females than males after adjusting for all covariates. Several patients also provided
personal anecdotes in the comments describing how a few physicians they encountered
were dismissive of their symptoms and concerns, which in many cases delayed their
diagnosis or treatment and affected their care. Empathetic care was extremely important
in shaping the patient experience.
Second, divorced or separated patients had the highest scores on all five domains
compared to other marital statuses. Married patients were least impacted by AF; widowed
or single patients consistently did better than divorced or separated patients. A study
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investigating the effect of divorce on mental and physical health, as measured by the
Short Form 36 (SF-36), found divorce to significantly impact the wellbeing of both men
and women9.

5.2 Implications
Good measurement development practices collect qualitative data directly from the target
population to generate candidate items for psychometric analysis. The MAP-AF
questionnaire that assesses the impact of AF on the lives of Canadian patients was
developed based on focus groups and interviews conducted across Canadian provinces.
Two other PROMs developed in Canada are the University of Toronto Atrial Fibrillation
Symptom Severity scale (AFSS) and the Atrial Fibrillation Effect on Quality-of-Life
(AFEQT). The AFEQT is a HRQoL questionnaire developed in both the US and Canada
that assesses AF symptoms, patients’ ability to perform daily activities, treatment
concerns, and treatment satisfaction. It has been used in clinical trials to measure QoL
changes due to interventions10,11,12. The MAP-AF questionnaire is unlike typical HRQoL
measures, as patient experiences and the impact of AF on broader realms of wellbeing
were measured. Our construct of interest is most similar to the Organisation for
Economic Co-operation and Development (OECD) PaRIS survey for chronic disease
patients, where both patient experiences and patient outcomes are measured in one
instrument1. Despite nuances in the construct measured, the AF impact that we assessed
shares similar predictors with (HR)QoL.
Our study demonstrated a statistically significant gender bias in AF diagnoses. Previous
reports of this phenomenon were from qualitative interviews13, and we were able to
support this observation with quantitative evidence. In line with results from the focus
groups and patient journey maps, female patients in our study more frequently felt
dismissed when communicating symptoms to physicians and found the diagnostic
process to be more difficult than male patients. Unfortunately, women were also less
likely to be offered or receive an ablation than men during the treatment phase7,8. The
literature consistently reports women to experience greater symptom severity and
frequency7,8, yet they are more likely than men to experience difficulties and delays in
diagnosis and treatment. One of the potential reasons for this observation is the perceived
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bias among healthcare providers14. A study found that women experiencing syncope, one
of the possible symptoms of AF, were often dismissed by Emergency Medical Services
as a symptom of feminine conditions like menstruation, menopause, or pregnancy14.
Further investigation into the factors contributing to gender differences in the patient
experience is warranted to achieve equitable and effective healthcare services.

5.3 Strengths and limitations
This study has several strengths, including the performance of sensitivity analyses,
additional exploratory analyses, collecting patient feedback on the questionnaire, high
completion rate, and survey features that allow a better understanding of missing data.
First, the results of exploratory factor analysis were robust to various data conditions. By
performing sensitivity analyses, we were able to see whether conclusions would change
under varying circumstances and justify our decisions.
Although the MAP-AF still needs to undergo extensive validation before its scores can be
meaningfully analyzed, we conducted many additional analyses that functioned to
generate hypotheses for future research.
The textbox included at the end of the online questionnaire also generated lots of
qualitative data. While we did not conduct a formal analysis of the data, the comments
provided by patients helped inform some of the limitations and future directions of our
study.
The MAP-AF questionnaires had a high completion rate of 87% and few missing data.
We show that web administration of surveys is feasible in our age demographic, which
had a mean of 63.8 years and a max of 83 years. The skip patterns, N/A options, and the
comment box features allowed us to categorize and better understand missing data.
A thorough investigation of missing values was done for the 24 items prior to EFA
(eleven highly irrelevant items were removed). Of 277 who took the questionnaire, 14
(5.1%) individuals did not answer at least one of the 24 items. Patients’ feedback
suggests some of the questions did not apply to their circumstances. Patients commented
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on how the questionnaire made assumptions about their experiences and how some
questions were difficult to answer because they no longer have AF. Some patients
indicated that they did not experience symptoms before they were diagnosed, rendering
them unable to answer the diagnosis-related questions. There were only four questions
among the 24 items with a N/A option. There were no missing values for these four items
– missing values only occurred where the N/A option was not available. Three of the 14
individuals with missing values have used the N/A option at least once. We speculate that
if a N/A option existed for the items they missed, they would have selected it instead. For
the remaining 11 individuals, the possible reasons for missingness were provided in the
results. Briefly, these include suboptimal question wording, the nearby presence of family
members, forgetfulness, and again, the lack of a N/A option when the question did not
apply.
There are also limitations to this study. These include sample selection, possible recall
bias, suboptimal design of clinical questions, lack of consideration for comorbidities, and
the effect of the current COVID-19 pandemic on social-related questions.
First, our sample is a convenience non-probability sample of 500 consecutive post-PVA
patients. Some patients were diagnosed a long time ago and no longer experienced AF.
Over half of the questionnaire respondents were diagnosed more than 5 years ago, and
another 30% diagnosed more than 3 years ago. Forty-one percent last experienced an
episode more than a year ago, and 42% recently experienced minimal to no symptoms.
Moreover, some incidentally diagnosed patients were included in our sample. For these
patients, some questions were difficult to answer.
There might have been substantial recall bias for patients who were either diagnosed a
long time ago or no longer experienced AF. It is also possible that the recall of memories
may have depended on the success of the ablation (or other treatments).
Next, the following questions were used to ascertain the clinical characteristics of our
patients:
“how often do you have an episode of atrial fibrillation”
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“when was the last time you had an episode of atrial fibrillation”
“how would you describe the severity of your symptoms as of recently”
These questions were particularly confusing for patients who no longer had atrial
fibrillation. We thought these patients would have responded to the above questions with
“less than one episode a year”, “last episode was more than 1 year ago”, and “minimal to
no symptoms as of recently”. However, we found the questions to be suboptimally
worded, such that some patients responded in a way that reflected their past AF burden
when they still had AF. We thus anticipate some misclassification to be present and a
greater proportion of patients with a lower AF severity and burden. In the future, a
question that clarifies whether respondents are still in atrial fibrillation or not may
remedy this problem. Respondents could then be directed to questions appropriate to
them. Alternatively, validated symptom scales could be used to capture the clinical
profile of our patients more accurately.
In addition to the above limitations, some patients had multiple arrhythmias and
comorbidities that made it difficult to attribute their reduced wellbeing to a particular
source like AF. For example, patients with both AF and atrial flutter found it difficult to
discern the effects between the two arrhythmias. Some of the other comorbidities that
were present in our sample include cardiomyopathy, supraventricular tachycardia,
chronic obstructive pulmonary disease, obstructive sleep apnea, and erectile dysfunction.
A few patients stated that their comorbidities had a greater impact on their life than their
AF. Comorbidities likely explain a portion of the variance in the MAP-AF scores, but
they were not measured in this study.
Questionnaire data was collected during the COVID-19 pandemic when lockdowns and
social distancing were imposed. The focus groups and patient journey mapping were
conducted during pre-pandemic times. The pandemic may have skewed responses to
questions about patients' social relationships and social life satisfaction. Some, not all,
patients answered as if the pandemic did not exist (i.e., what life would be like in prepandemic times).
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Last, we did not factor analyze employment-related questions because they were not
applicable to greater than 10% of our patient population. Our next steps would be to
conduct a separate EFA on all 35 items using a smaller subset of 159 participants to
whom employment-related questions applied.

5.4 Improvements of the MAP-AF
In addition to addressing the limitations described above, we also summarize patients’
feedback and suggestions for improvement.
In the comments section, many patients described their personal experiences and
mentioned concerns unaddressed by the MAP-AF.
First, the MAP-AF did not adequately explore the stress of the treatment phase, which
primarily comes from negative experiences with the healthcare system and the side
effects or ineffectiveness of treatment. Many patients mentioned the long waitlist for an
ablation – a patient described getting cardioverted seven times while waiting for an
ablation. These patients signed up for an ablation in many cases because the side effects
of medications were intolerable. For example, the physical functioning and energy levels
of some patients deteriorated, and many were unable to pursue their desired lifestyle. The
difficulty of getting an ablation, an appointment, or a referral can greatly delay treatment
and worsen prognosis. Patients also mentioned the inconsistent approaches to
management from the many physicians they see and inconsistent experiences in
emergency departments. However, not all patients’ experiences were negative. Several
patients expressed that the empathetic and compassionate care they received outweighed
any costs or inconveniences associated with their condition and treatment. This further
reinforces the importance of considering both experiences with practical aspects of care
(i.e., patient experiences) and effects of care (i.e., patient outcomes).
Second, patients described additional effects of AF that were not outlined in the MAPAF. These included the effect of AF on their sleep and their fulfillment of their sexual
lives. Most frequently mentioned was the inability to perform their desired level of
physical activity. This significantly affected the patient’s health, autonomy (e.g., unable
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to drive a car and go shopping alone), and social life. Even for patients who had a
successful ablation and were able to return to an active lifestyle, they worried about
whether AF would return due to them being active again.
In general, there was considerable uncertainty surrounding AF, which produced anxiety
for many patients.

5.5 Conclusion and future directions
The MAP-AF questionnaire was developed and initially validated in a sample of postpulmonary vein ablation patients with AF in London, Ontario. The questionnaire contains
16 items and five domains: “Affect”, “Social Support”, “Major Life Events”, “Financial
Impact”, “Diagnostic Experience”. Younger age, being divorced or separated, having a
lower education, and experiencing more recent episodes were associated with a more
negative patient journey. While the effect of gender on overall AF impact appears to be
confounded by the time of last AF episode, gender was nevertheless an important
predictor for the patient’s diagnostic experience. Confirming previous qualitative
findings, female patients were more likely to have their symptoms dismissed and report
having a more difficult time trying to get a diagnosis than male patients. Healthcare
professionals should increase their awareness of the challenges associated with symptom
onset and their own affective responses to patients presenting with palpitations and other
AF symptoms. Timely diagnosis and treatment initiation are goals shared by both patients
and physicians.
Our study demonstrates the importance of studying both patient experiences and
outcomes of care. More research is needed to understand the lived experiences of patients
with AF – a condition that is associated with a lot of uncertainties. The next steps for this
study include revising the MAP-AF based on patient feedback (e.g., expanding the
questionnaire to cover employment effects and treatment impacts) and administer the
new questionnaire in a separate sample to obtain more evidence supporting the validity of
the measure to assess the AF patient experiences and promote better AF management.
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Appendix C: Demographic and clinical questions
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Appendix D. Scree plots from four different datasets

CCA

CCA with log transformed item 25

EM imputed dataset

EM with log transformed item 25

CCA = complete case analysis (n = 229); EM = expectation maximization imputation
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Appendix E. Rotated factor pattern solutions of a five-factor extraction under various conditions
Factor

iPAF
Promax
CCA

iPAF
Promax
EM imputation

ULS
Promax
CCA

ULS
Promax
EM imputation
7, 27, 28, 29, 30,
31, 32

iPAF
Promax
CCA
Log(item 25)
7, 27, 28, 29, 30,
31, 32

iPAF
Promax
EM imputation
Log(item 25)
7, 27, 28, 29, 30,
31, 32

ULS
Promax
CCA
Log(item 25)
7, 27, 28, 29, 30,
31, 32

ULS
Promax
EM imputation
Log(item25)
7, 27, 28, 29, 30,
31, 32

1

7, 27, 28, 29, 30,
31, 32

7, 27, 28, 29, 30,
31, 32

7, 27, 28, 29, 30,
31, 32

2

13b, 14, 15, 21,
22, 23b, 24 ,25,
26

13b, 14, 15, 21,
22, 23b, 24,25,
26

13b, 14, 15, 21,
22, 23b, 24 ,25,
26

13b, 14 ,15, 21,
22, 23b, 24, 25,
26

13b, 14, 15, 21,
22, 23b, 24 ,25,
26

13b, 14, 15, 21,
22, 23b, 24 ,25,
26

13b, 14, 15, 21,
22, 23b, 24 ,25,
26

13b, 14, 15, 21,
22, 23b, 24 ,25,
26

3
19, 33, 34
19, 33, 34
19, 33, 34
19, 33, 34
19, 33, 34
19, 33, 34
19, 33, 34
19, 33, 34
4
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
b
b
b
b
b
b
b
b
b
b
b
b
b
b
5
3, 5, 6, 13 , 23
3, 5, 6, 13 , 23
3, 5, 6, 13 , 23
3, 5, 6, 13 , 23
3, 5, 6, 13 , 23
3, 5, 6, 13 , 23
3, 5, 6, 13 , 23
3, 5, 6, 13b, 23b
The cells indicate items with a rotated factor loading of greater than 0.35 on the particular factor.
a Item has a rotated factor loading greater than 0.32, but less than 0.35 – indicating poor loading on the particular factor.
b Cross-loading items (items that load on more than one factor)
CCA = complete-case-analysis; EM = expectation maximization (maximum likelihood estimation) imputation; iPAF = iterative principal axis factoring; ULS
= unweighted least squares
Interpretation: Extraction methods iPAF and ULS produced identical conclusions; EM imputation did not differ from CCA; log transformation did not produce
differences
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Appendix F. Rotated factor pattern solutions of a six-factor extraction under various conditions
Factor

iPAF
Promax
CCA

iPAF
Promax
EM imputation

ULS
Promax
CCA

ULS
Promax
EM imputation

1

7b, 27, 28, 29,
30, 31b, 32

7b, 27, 28, 29,
30, 31b, 32

7b, 27, 28, 29,
30, 31b, 32

7b, 27, 28, 29,
30, 31b, 32

iPAF
Promax
CCA
Log(item 25)
7b, 27, 28, 29,
30, 31b, 32

iPAF
Promax
EM imputation
Log(item 25)
b
7 , 27, 28, 29,
30, 31b, 32

ULS
Promax
CCA
Log(item 25)
7b, 27, 28, 29,
30, 31b, 32

ULS
Promax
EM imputation
Log(item25)
b
7 , 27, 28, 29,
30, 31b, 32

2

22, 23, 24, 25,
26, 31ab

22, 23, 24, 25,
26, 31ab

22, 23, 24, 25,
26, 31b

22, 23, 24, 25,
26, 31ab

22, 23, 24, 25b,
26, 31ab

22, 23, 24, 25b,
26, 31ab

22, 23, 24, 25b,
26, 31ab

22, 23, 24, 25b,
26, 31ab

3
4

19, 33, 34
7ab, 13, 15, 21

19, 33, 34
7b, 13, 15, 21

19, 33, 34
7ab, 13, 15, 21

19, 33, 34
7b, 13, 15, 21

19, 33, 34
7ab, 13, 14a, 15,
21, 25ab

19, 33, 34
7b, 13, 14a, 15,
21, 25ab

19, 33, 34
7ab, 13, 14a, 15,
21, 25ab

19, 33, 34
7b, 13, 14a, 15,
21, 25ab

5
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
The cells indicate items with a rotated factor loading of greater than 0.35 on the particular factor.
a Item has a rotated factor loading greater than 0.32, but less than 0.35 – indicating poor loading on the particular factor.
b Cross-loading items (items that load on more than one factor)
CCA = complete-case-analysis; EM = expectation maximization (maximum likelihood estimation) imputation; iPAF = iterative principal axis factoring; ULS
= unweighted least squares
Interpretation: Extraction methods iPAF and ULS produced identical conclusions; EM imputation strengthened the loading of item 7 on Factor 4; log transformation
of item 25 added two poor loading items, item 14 and item 25, to Factor 4.
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Appendix G. Rotated factor pattern solutions of a seven-factor extraction under various conditions
Factor

iPAF
Promax
CCA

iPAF
Promax
EM imputation

ULS
Promax
CCA

ULS
Promax
EM imputation

1

7, 27, 28, 29,
30ab, 31, 32

7, 27, 28, 29,
30ab, 31, 32

7, 27, 28, 39,
30ab, 31, 32

7, 27, 28, 39,
30ab, 31, 32

iPAF
Promax
CCA
Log(item 25)
7, 27, 28, 29,
30ab, 31, 32

iPAF
Promax
EM imputation
Log(item 25)
7, 27, 28, 29,
30ab, 31, 32

ULS
Promax
CCA
Log(item 25)
7, 27, 28, 29,
30ab, 31, 32

ULS
Promax
EM imputation
Log(item25)
7, 27, 28, 29,
30ab, 31, 32

2

22, 23, 30ab

22, 23, 24a, 30ab

22, 23, 30ab

22, 23, 24ab, 30ab

22, 23, 30b

22, 23, 24ab, 30ab

22, 23, 30b

22, 23, 24ab, 30ab

3
4

19, 33, 34
14, 15ab, 24, 25,
26

19, 33, 34
14, 15ab, 24b, 25,
26

19, 33, 34
14, 15ab, 24, 25,
26

19, 33, 34
14, 15ab, 24b, 25,
26

19, 33, 34
14, 15ab, 24, 25,
26

19, 33, 34
14, 15ab, 24b, 25,
26

19, 33, 34
14, 15ab, 24, 25,
26

19, 33, 34
14, 15ab, 24b, 25,
26

5
13, 15b, 21
13, 15b, 21
13, 15b, 21
13, 15b, 21
13, 15b, 21
13, 15b, 21
13, 15b, 21
13, 15b, 21
6
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
1, 2
7
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
3, 5, 6
The cells indicate items with a rotated factor loading of greater than 0.35 on the particular factor.
a Item has a rotated factor loading greater than 0.32, but less than 0.35 – indicating poor loading on the particular factor.
b Cross-loading items (items that load on more than one factor)
CCA = complete-case-analysis; EM = expectation maximization (maximum likelihood estimation) imputation; iPAF = iterative principal axis factoring; ULS
= unweighted least squares
Interpretation: iPAF and ULS produced identical conclusions; EM imputation added a poor loading item 24 to Factor 2; log transformation of item 25 increased the
factor loading of item 30 for Factor 2 under CCA
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